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Abstract 
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class 
for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, 
are now approved by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs 
are still under development, making for a crowded marketplace and fierce competition among 
the manufacturers of these products. As rapid elimination is a major challenge for clinical 
application of GLP-1 RAs, various half-life extension strategies have been successfully 
employed including sequential modification, attachment of fatty-acid to peptide, fusion with 
human serum albumin, fusion with the fragment crystallizable (Fc) region of a monoclonal 
antibody, sustained drug delivery systems, and PEGylation. In this review, we discuss the 
scientific rationale of the various half-life extension strategies used for GLP-1 RA development. 
By analyzing and comparing different approved GLP-1 RAs and those in development, we focus 
on assessing how half-life extending strategies impact the pharmacokinetics, 
pharmacodynamics, safety, patient usability and ultimately, the commercial success of GLP-1 
RA products. We also anticipate future GLP-1 RA development trends. Since similar drug 
delivery strategies are also applied for developing other therapeutic peptides, we expect this 
case study of GLP-1 RAs will provide generalizable concepts for the rational design of 
therapeutic peptides products with extended duration of action. 
 
Keywords: GLP-1 receptor agonist; exenatide; peptide delivery; half-life; 
pharmacokinetics; fatty acid conjugate; albumin fusion; Fc fusion. 
 
1.  Introduction 
Type-2 diabetes is a chronic metabolic disease characterized by hyperglycemia, reduced 
insulin secretion, and insulin resistance. If not properly treated, type 2 diabetes can result in 
serious or even fatal complications including blindness, limb amputation, kidney failure, and 
cardiovascular diseases. In 2017, the International Diabetes Federation estimated that, globally, 
423 million people between the ages of 20 and 79 had diabetes [1], and that type 2 diabetes 
comprised about 90% of these cases [2]. That same year, the global economy spent an 
estimated 727 billion USD for diabetes treatment [1]. As both diabetes diagnoses and the life 
expectancy of individuals with diabetes continue to rise, the total number of diabetic patients is 
expected to reach 629 million by 2045 [1], resulting in an increasing demand for anti-diabetes 
therapies.  
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Historically, metformin has remained the first-line treatment for type 2 diabetes. Other long-
used therapeutic options to help manage glucose levels include insulin, sulphonylureas, and 
thiazolidinediones [3]. However, maintaining glucose homeostasis with these agents remains 
challenging for many patients [4]. Furthermore, some of these drugs—particularly insulin and 
sulfonylurea—lead to undesired risks including hypoglycemia and weight gain [5]. Thus, 
identifying new drug targets and developing more effective and safer treatments is necessary to 
achieve optimal management of type 2 diabetes. 
Glucagon-like peptide-1 (GLP-1) emerged as a target for type-2 diabetes treatment due to 
its unique mechanism of action. GLP-1 is an endogenous incretin hormone produced by 
intestinal enteroendocrine L-cells following nutrient ingestion [6]. The initial product, GLP-1 (1-
37), is quickly cleaved by enzymes, resulting two active truncated forms GLP-1 (6-37) and GLP-
1 (7-37) [7, 8]. GLP-1 exerts multiple physiological effects by activating GLP-1 receptors 
distributed in various organs, including the pancreas, gastrointestinal (GI) tract, brain, heart and 
the kidneys [7, 9]. When glucose levels are elevated, GLP-1 promotes insulin secretion in the 
pancreas but has minimal effect when glucose levels are normal [10]. This glucose-dependent 
insulinotropic effect is particularly favorable for diabetes treatment because it avoids the risks of 
hypoglycemia, a common side effect of some anti-diabetes drugs, including insulin [10]. GLP-1 
also decreases glucagon secretion, further contributing to reduction of glucose levels [11, 12]. 
Studies have also suggested that GLP-1 can improve E-cell function and inhibit E-cell apoptosis, 
both of which could prevent or slow the progression of E-cell failure in type 2 diabetes [11, 13, 
14]. GLP-1 also displays positive effects on other tissues and organs. In the GI tract, GLP-1 
slows gastric emptying, leading to lower postprandial glucose levels [15, 16]. By activating GLP-
1 receptors in the nervous system, GLP-1 could enhance satiety and inhibit energy intake, 
which may help reduce bodyweight [17, 18]. 
Despite its potent anti-diabetes effects, the clinical application of native GLP-1 is hindered 
by its rapid clearance by the dipeptidyl peptidase-4 (DPP-4) enzyme in vivo, resulting in a half-
life of only 2 minutes [19, 20]. GLP-RA developers have applied various half-life extending 
strategies and some of them have successfully resulted in FDA-approved diabetes products. 
Simple sequential modification enhances DPP-4 resistance and improves GLP-1 receptor 
activation potency. This strategy led to the twice-daily and once-daily products, Byetta® and 
Adlyxin®, respectively. Sequence modification to enhance DPP-4 resistance combined with 
covalent attachment of a fatty acid leads to slower absorption and mediates albumin binding in 
plasma, a strategy employed in the development of the once-daily and once-weekly agents, 
Victoza® and Ozempic®, respectively. More complicated molecular modifications that led to the 
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approval of once-weekly products include fusing either recombinant human serum albumin 
(Tanzeum®) or an antibody fragment crystallizable (Fc) moiety (Trulicity®) to a GLP-1 analog. 
Other GLP-1 modifications have also been tested, including GLP-1 RA modified either with a 
recombinant peptide polymer XTEN® (VRS-859) or polyethylene glycol (LY2428757). Both 
molecules progressed into clinic trials, leading to the possibility of once-monthly and once-
weekly products, but the development of these molecules appears to have been halted. 
Controlled release GLP-RA products have also been developed including the FDA-approved 
once-weekly poly(lactide-co-glycolide) microspheres (Bydureon®) and a once-yearly titanium 
implant (ITCA 650) which is currently under review by the FDA.   
The employment of different half-life extension strategies, thus, results in significant 
differences in the pharmacokinetic profiles, efficacy, safety, and usability of these products, 
which in turn largely impacts the use and market penetration of GLP-1 RA products. In this 
review, we discuss the structure-activity relationship, pharmacokinetics, efficacy and market 
dominance of approved GLP-1 RA products, GLP-1 RA molecules in development and 
combination therapy strategies. The implementation of various creative delivery technologies for 
improving circulation half-life of molecules will likely be repeated for other peptide or protein 
products, making this review relevant for scientists working within the drug delivery field.
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 Table 1. O
verview
 of G
LP-1 R
As on the m
arket for type 2 diabetes treatm
ent. 
Drug nam
e 
Brand nam
e 
Adm
inistration 
Dosage 
FDA 
Approval 
Com
pany 
E
xenatide 
B
yetta®
 
Tw
ice a day (S
Q
) 
Initiate at 5 Pg/dose (equivalent to 1.2 nm
ol G
LP
-1 R
A
 per dose). The 
dose can be increased to 10 Pg/dose (2.4 nm
ol/dose) after 1 m
onth. 
[21] 
A
pr 2005 
A
straZeneca 
Liraglutide 
V
ictoza®
 
O
nce a day (S
Q
) 
Initiate at 0.6 m
g/dose (equivalent to 0.16 Pm
ol G
LP
-1 R
A
 per dose) for 
one w
eek then increase to 1.2 m
g/dose (0.32 Pm
ol/dose). D
ose can be 
increased to 1.8 m
g/dose for additional glycem
ic control (0.48 
Pm
ol/dose). [22] 
Jan 2010 
N
ovo N
ordisk 
E
xenatide 
B
ydureon®
 
O
nce w
eekly (S
Q
) 
2 m
g/dose (equivalent to 0.48 Pm
ol G
LP
-1 R
A
 per dose). [23] 
Jan 2012 
A
straZeneca 
A
lbiglutide 
Tanzeum
®
 (U
S
) 
E
perzan®
 (E
U
) 
O
nce w
eekly (S
Q
) 
Initiate at 30 m
g/dose (equivalent to 0.82 Pm
ol G
LP
-1 R
A
 per dose); 
D
ose can be increased to 50 m
g/dose (1.4 Pm
ol/dose). [24] 
A
pr 2014 
G
laxoS
m
ithK
line 
D
ulaglutide 
Trulicity®
 
O
nce w
eekly (S
Q
) 
Initiate at 0.75 m
g/dose (equivalent to 0.024 Pm
ol G
LP
-1 R
A
 per dose); 
D
ose can be increased to 1.5 m
g/dose (0.048 Pm
ol/dose). [25] 
S
ep 2014 
E
li Lilly &
 C
o 
Lixisenatide 
A
dlyxin®
 (U
S
) 
Lyxum
ia®
 (E
U
) 
O
nce a day (S
Q
) 
Initiate at 10 Pg/dose (equivalent to 2.06 nm
ol G
LP
-1 R
A
 per dose). O
n 
day 15, increase to 20 Pg/dose (4.12 nm
ol/dose). [26] 
Jul 2016 
S
anofi-A
ventis 
S
em
aglutide 
O
zem
pic®
 
O
nce w
eekly (S
Q
) 
Initiate at 0.25 m
g/dose (equivalent to 0.061 Pm
ol G
LP
-1 R
A
 per dose), 
increase up to 1 m
g/dose (0.24 Pm
ol/dose) after 4 w
eeks. [27] 
D
ec 2017 
N
ovo N
ordisk 
Com
bination Products (GLP-1 RA + Insulin) 
Liraglutide 
and insulin 
degludec 
Xultophy®
 
100/3.6 
O
nce a day (S
Q
) 
R
ecom
m
ended starting dosage is 16 units of insulin degludec and 0.58 
m
g (0.15 Pm
ol) of liraglutide per day. M
axim
um
 daily dosage is 50 units 
of insulin degludec and 1.8 m
g (0.48 Pm
ol) of liraglutide. [28] 
N
ov 2016 
N
ovo N
ordisk 
Lixisenatide 
and insulin 
glargine 
S
O
LIQ
U
A
®
 
100/33 
O
nce a day (S
Q
) 
Initiate at 15 units insulin glargine/5 Pg (1.03 nm
ol) lixisenatide or at 30 
units insulin glargine/10 Pg (2.06 nm
ol) lixisenatide. M
axim
um
 daily 
dose is 60 units insulin glargine/20 Pg (4.12 nm
ol) of lixisenatide. [29] 
N
ov 2016 
S
anofi-A
ventis 
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Figure 1. Peptide sequences and molecular structures of FDA approved GLP-1 RAs. 
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Table 2. GLP-1 RAs pharmacokinetics parameters  
Product 
name Dose Tmax Vd T1/2 AUC CL Ref 
Exenatide BID  
Byetta® 
Single dose of 
10 Pg 2.1 h 28.3 L 2.4 h 1036 pg•h/ml 9.1 L/h [21] 
Lixisenatide 
Adlyxin® N.A. 1-3.5 h 100 L 3 h N.A. 35 L/h [26] 
Liraglutide 
Victoza® 
Single dose of 
0.6 mg 8-12 h 13 L 13 h 960 ng•h/ml 1.2 L/h [22] 
Semaglutide 
Ozempic® 
Single dose of 
0.5 mg 56 h 9.4 L 7 days 3123 nmol•h/L
 0.039 L/h [30] 
Albiglutide 
Tanzeum® 
Single dose of 
30 mg 3-5 d 11 L 5 days 465 Pg•h/ml
 0.067 L/h [24] 
Dulaglutide 
Trulicity® 
Multiple doses 
of 1.5 mg to 
steady state 
24-72 h 17.4 L 5 days 14 Pg•h/ml 1.07 L/h [25] 
Exenatide QW 
Bydureon® 
Multiple doses 
of 2 mg to 
steady state 
Css = 300 pg/ml; Tss = 6~7 weeks [23] 
ITCA 650 
Continuous 
delivery of 20 
Pg/day 
Css = 75.8 pg/ml [31] 
Abbreviations: Tmax: time to reach peak plasma concentration after administration; Vd: apparent volume of 
distribution; AUC: area under the curve for peptide concentration in plasma, CL: clearance; Css: average 
peptide concentration at the steady state; Tss: time to reach steady state after administration. 
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2. Strategies to increase half-life 
To design GLP-RAs with an increased circulation time, a broad array of half-life extension 
strategies has been utilized including sequential modification (Byetta® and Adlyxin®), 
attachment of a fatty-acid (Victoza® and Ozempic®), development of a polymer-based 
sustained release formulation (Bydureon®), fusion with human serum albumin (Tanzeum®), 
and fusion with the fragment crystallizable (Fc) region of a monoclonal antibody (Trulicity®). In 
this section we review the structure-activity relationship behind the various half-life extending 
strategies in the context of GLP-1 RA development and, in turn, how these modifications impact 
pharmacokinetic parameters and dosing scheduling of the resulting GLP-1 RA products.   
 
2.1 Critical structural elements of GLP-1 sequence 
Early structure-activity studies of endogenous GLP-1 revealed the key sequence domains 
that correlate with potency and enzymatic degradation. Studies have suggested that the N-
terminal residues His7, Gly10, Phe12, Thr13 and Asp15 are essential for interaction with the 
GLP-1 receptor, as substituting these residues with L-Ala leads to a severe loss of affinity for its 
receptor [32]. Similarly, C-terminal positions Phe28 and Ile29 are also important for receptor 
binding due to their role in maintaining the peptide’s secondary structure [32]. Endogenous 
GLP-1 has a short plasma half-life because of its rapid degradation by DPP-4, which cleaves 
GLP-1 between the Ala8 and Glu9 amino acids [33]. In addition, neutral endopeptidase (NEP) 
plays a minor role in GLP-1 degradation by cleaving at six sites, Asp15-Val16, Ser18-Tyr19, 
Tyr19-Leu20, Glu27-Phe28, Phe28-Ile29 and Trp31-Leu32, within the central and C-terminal 
peptide domains [33]. 
Based on structure-activity studies, many GLP-1 analogs have been designed to evade 
enzymatic degradation while maintaining their potency. Because DPP-4 cleavage at Ala8-Glu9 
is the major reason for the rapid deactivation of native GLP-1, replacing Ala8 is a commonly 
used strategy to reduce DPP-4 degradation. For example, replacing Ala8 with a-aminoisobutyric 
acid (Aib) was found to completely prevent DPP-4 degradation [34]. Similarly, in two other 
commercialized GLP-1 analogs, albiglutide and dulaglutide, Ala8 is substituted with Gly to 
prevent DPP-4 degradation (Figure 1). 
 
2.2 Exendin-4 and its analogs 
In addition to human GLP-1 analogs, a naturally-occurring peptide and a hormone found in 
the saliva of Gila monster (a venomous lizard), exendin-4, was identified as a GLP-1 RA (Figure 
1). Although exendin-4 shares only 53% homology with human GLP-1, in vitro studies 
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demonstrated that exendin-4 has a slightly higher potency than native GLP-1 [35], attributable to 
their high similarity of key N-terminal residues. Compared to native GLP-1, exendin-4 is more 
resistant to cleavage by DPP-4 due to a Gly to Ala substitution at the second position [36]. 
Furthermore, the Leu29-Ser39 segment of exendin-4 can form a tertiary fold, or “Trp cage”, 
which conformationally shields residues 21-39, protecting these sites from being cleaved by 
NEP 24.11 [37, 38]. The enzyme resistance results in a distinct metabolic pathway of exendin-4. 
Studies reported that exendin-4 is mainly degraded on kidney membranes and eliminated via 
glomerular filtration [39, 40]. In comparison, native GLP-1 is eliminated by both the kidneys and 
liver while also subject to metabolism in peripheral tissues.   
Exenatide, a synthetic version of exendin-4, was the first GLP-1 RA to be approved by the 
FDA under the brand name of Byetta® (Table 1). In 2009, Byetta®  was approved as a stand-
alone therapy for type 2 diabetes by the FDA [21]. Byetta® is administered as a twice daily 
(BID) subcutaneous injection before each main meal. Patients begin with a 5 Pg dose for one 
month, followed by titration up to 10 Pg [21]. Pharmacokinetic parameters of exenatide are 
summarized in Table 2. Peak plasma concentration is achieved about 2 hours post 
administration. The product half-life is 2.4 hours, which allows for twice daily administration, and 
is a large improvement over endogenous GLP-1 [21]. Animal studies have shown that exenatide 
is mainly cleared by renal filtration.  
Another successful GLP-1 RA, lixisenatide, was launched in the U.S. in July 2016 under the 
brand name Adlyxin® (Table 1). Modified from exendin-4, lixisenatide is a 44-amino-acid 
peptide with the C-terminal Pro replaced by 6 Lys residues (Figure 1). In vitro studies found that 
lixisenatide has four times greater affinity for the GLP-1 receptor than native GLP-1 and 
exenatide [41]. Lixisenatide is administered once daily at 10 – 20 Pg per day (Table 1). The 
pharmacokinetic profile of lixisenatide is similar to that of exenatide with a characteristic kidney 
elimination and Tmax of 2 hours post administration. The apparent volume of distribution is 100 
L, with approximately 55% of lixisenatide bound to plasma proteins in circulation (Table 2) [26]. 
The half-life of lixisenatide is 2.6 hours, which is similar to that of exenatide [26]; however, unlike 
exenatide, lixisenatide is indicated as a once-daily injection. This is partly due to lixisenatide’s 
better ability to slow gastric emptying, yielding a better glucose control and, thus, reduced 
administration frequency [42].  
Although amino acid substitution is an effective strategy to reduce proteolytic degradation, 
modified GLP-1 analogs are still subject to rapid renal clearance, making it difficult to further 
prolong peptide circulation time. Thus, other drug delivery strategies were used to develop 
longer-acting GLP-1 RAs, as described below. 
10 
 
 
2.3 Fatty acid conjugates 
Covalent attachment of a fatty acid, known as acylation, is used extensively to control the 
half-life of therapeutic peptides [43]. One example is the insulin detemir (Levemir®), in which 
myristic acid is introduced to insulin at position B29. The conjugation of myristic acid results 
half-life extension from 4-6 min (insulin) to 5-7 hours (insulin detemir). 
Acylation with fatty acids can increase the circulation time of therapeutic peptides by 
several mechanisms. First, acylated peptides could self-assemble to supramolecular structures 
due to their amphiphilic nature. Once subcutaneously injected, acylated peptide spontaneously 
forms a depo at the injection site, leading to a delayed absorption into systemic circulation [44]. 
In the case of acylated GLP-1 RAs, it was reported that liraglutide, a palmityolated GLP-1 RA, 
could self-assemble into hexa-, hepta- or octamers, depending on the pH and ionic strength [45-
47]. When the acylated peptide monomer finally dissociates from the oligomer and enters blood 
circulation, it readily yet reversibly binds to serum albumin through hydrophobic and ionic 
interactions between the fatty acids and albumin [48, 49]. Albumin binding provides steric 
hindrance against enzymatic degradation of the acylated peptide and slows its renal clearance 
due to the large size of the peptide-albumin complex. The albumin-bound peptide is also 
hypothesized to interact with the neonatal Fc receptor (FcRn), allowing it to shuttle through the 
albumin recycling pathway and evade intracellular degradation, thus, significantly increasing the 
circulation half-life [50]. However, although the FcRn recycling is proposed as a half-life 
extension mechanism for albumin-bound peptides in general, to the best of our knowledge there 
is no existing experimental evidence that proves FcRn recycling occurs for acylated GLP-1 RAs. 
The stability and potency of acylated GLP-1 RAs depends on the site of acylation, the 
bulkiness and length of the fatty acid chains, and the spacer used between the peptide and fatty 
acid [51-53]. Because the N-terminus is key for receptor binding and activation, acylation in the 
N-terminal region leads to serious loss of potency. In contrast, C-terminal modifications have 
little impact on potency [52]. The spacers linking peptide segment and fatty acid chains also 
greatly affect the potency of acylated GLP-1 RAs [53]. While the bulkiness of fatty acid was 
found to negatively impact the potency of GLP-1 RAs, the length of the fatty acid had more 
complex effects [53]. The length of fatty acid chain is positively correlated with the binding 
affinity to albumin, leading to a longer circulation time [51, 53]. However, the peptide must 
dissociate from albumin to activate GLP-1 receptor, thus GLP-1 RAs with longer fatty acid chain 
exhibit lower potency in the presence of serum [52, 53]. Therefore, the acylation site and the 
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length of fatty acid chain must be selected to achieve the right balance between potency and in 
vivo stability. 
The most successful example of an acylated GLP-1 is liraglutide, which was approved by 
the FDA in 2010 under the brand name Victoza®. Liraglutide, derived from native GLP-1, has a 
16-C fatty acid linked to Lys26 with a γ-Glu spacer and substituting Arg for Lys at position 34 
[54]. Once administered, the fatty acid chain causes oligomerization of liraglutide, enabling 
formation of oligomers at the injection site [45, 47]. The self-association of liraglutide leads to 
delayed absorption into systemic circulation, which was observed in clinical studies where 
intravenously administered liraglutide was found to have a shorter residence time than when 
administered subcutaneously [55, 56]. In plasma, liraglutide monomers dissociate from the 
oligomers [56] and bind to albumin within the central blood compartment [57]. In vitro studies 
showed that while liraglutide could be metabolized by DPP-4 and NEP in a manner similar to 
GLP-1, its degradation was much slower [58], possibly due to the steric hindrance provided by 
fatty-acid-bound albumin. Albumin binding also prevents renal filtration of liraglutide, evidenced 
by the fact that no intact liraglutide could be detected in patients’ urine in clinical studies [58]. 
Combined, these factors all contribute to enhance the in vivo stability of liraglutide. 
Pharmacokinetic data showed that liraglutide has a longer half-life, about 9-13 hours [22], 
compared to the other short-acting GLP-1 Ras, such as exenatide (2.1 hours) [21]. This affords 
liraglutide the ease of once-daily injections. Pharmacokinetic analysis also suggests that, 
compared to exenatide BID, liraglutide has smaller peak-to-trough fluctuations and better 
continuous exposure [55]. Liraglutide (Victoza®) is approved in the U.S. as a second-line type 2 
diabetes treatment (Table 1). Patients initiate the treatment with a 0.6 mg/dose for one week 
then increase to a 1.2 mg/dose. The dose can be increased to a 1.8 mg/dose for additional 
glycemic control. In addition, a higher dose liraglutide (3 mg/dose) has also been approved by 
the FDA for weight management under the brand name Saxenda® [16]. 
Semaglutide—which was approved by the FDA in December 2017 under the brand name of 
Ozempic®—is a next generation GLP-1 RA based on liraglutide. Compared to liraglutide, 
semaglutide has an additional amino acid substitution in the 8th position from Ala to D-
aminobutyric acid (Aib) to avoid degradation by DPP-4 [53]. A longer stearic (C18) di-acid fatty 
chain was introduced into semaglutide, whereas liraglutide has a C16 fatty acid [53]. The spacer 
between the stearic di-acid chain and peptide backbone has been optimized [51], and the 
spacers composed of γGlu or 8-amino-3,6-dioxaoctanoic acid (ADO) were found to be optimal 
for the potency of GLP-1 RAs, though mechanisms are not clear. For semaglutide, the fatty di-
acid chain is attached to Lys26 through one glutamic acid and two 8-amino-3,6-dioxaoctanoic 
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acid (ADO) moieties to achieve the optimal binding affinity [53]. Semaglutide shows a higher 
albumin binding affinity in comparison to liraglutide, which may be a result of the longer fatty 
acid side chain included in semaglutide [53]. The GLP-1 receptor binding affinity of semaglutide 
is slightly lower than that of liraglutide, which can be attributed to the longer lipid chain and 
presence of the terminal acid group on steric acid [53]. In clinical studies, semaglutide was 
shown to be degraded by enzymes prior to renal extraction. Because of its slow enzyme 
degradation and reduced renal extraction, semaglutide has a half-life of 7 days, allowing for 
once-weekly administration [59]. Despite the reduced dosing frequency, the dose of 
semaglutide — initially 0.25 mg/dose with the ability to increase to 1.0 mg/dose—is lower than 
that of liraglutide, which starts with a 0.6 mg/dose [27].  
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Figure 2. (A) Half-life extension mechanisms of acylated GLP-1 analogs. (B) Mean 
concentration-time profile of liraglutide following single dose of 0.6 mg, 1.2 mg, or 1.8 mg at 
steady state in healthy male Chinese subjects. Adapted with permission of © John Wiley & 
Sons, Inc. from Jiang et al. J Clin Pharmacol. 2011;51:1620–7. [60] (C) Mean concentration-
time profile of semaglutide following single dose of 1.0 mg at steady-state. Adapted with 
permission of © John Wiley & Sons, Inc. from Kapitza et al. J Clin Pharmacol. 2015; 55(5):497-
504. [61] 
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2.4 Albumin fusion 
Albumin is well-recognized as a potential carrier of therapeutic peptides due to its long 
circulation half-life, ability to distribute broadly in the body and low immunogenicity. This strategy 
has been successfully used in the development of the FDA-approved drug Idelvion  (albumin 
fusion of coagulation factor IX) [62]. Albumin conjugation likely improves GLP-1 RA plasma half-
life by several mechanisms, including providing steric hindrance from proteolysis and increasing 
molecular weight to reduce kidney filtration (Figure 2). In addition, covalent attachment to 
albumin may also prolong the peptide’s circulation time by a unique albumin recycling pathway 
through the neonatal Fc receptor (FcRn) [63]. Following endocytosis by endothelial cells, 
albumin binds to the FcRn receptor within the acidic lysosomal environment, which enables 
albumin rescue from degradation, transport back to the cell’s surface and return to the 
circulation [63, 64]. Such a recycling mechanism is believed to contribute to the prolonged half-
life of endogenous albumin and, presumably, albumin-fusion proteins [65]. 
An albumin conjugation strategy was used to design albiglutide (Tanzeum®), which was 
approved by the FDA in 2014. Albiglutide is a recombinant protein composed of two copies of 
GLP-1 analogs fused to human albumin. The molecule has a Gly8 to Ala substitution in both 
copies of the GLP-1 analogs to improve resistance to DPP-4 degradation. Albiglutide is 
administered once weekly by subcutaneous injection and is thought to be absorbed through the 
lymphatic circulation [24]. The peak plasma concentration is achieved about 4 days after a 
single administration, and steady-state is obtained after the first 3-4 weekly doses [24]. Due to 
its high molecular weight, renal filtration is not expected to be an important elimination 
mechanism for albiglutide. Overall, albiglutide has an in vivo half-life of 6-8 days, and is 
approved for once-weekly administration. Patients are initiated at 30 mg/dose (equivalent to 
0.82 Pmol GLP-1 RA per dose) and can be increased to 50 mg/dose (1.37 Pmol/dose) if 
necessary [24]. 
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Figure 3. (A) Half-life extension mechanisms of albiglutide. (B) Mean concentration-time profile 
of albiglutide following a single subcutaneous 30 mg injection. Adapted with permission of © 
2015 Taylor & Francis Ltd. from Young et al. Postgraduate Medicine. 126:7, 84-97. 
www.tandfonline.com [66]. 
 
2.5 Fc fusion 
Fc fusion is another established strategy to prolong the half-life of therapeutic peptides. 
Several Fc fusion products, such as etanercept (TNFR-Fc fusion protein, Enbrel®) and 
aflibercept (VEGFR-Fc fusion, Zaltrap®), are approved by the FDA [67]. Overall, incorporating 
the Fc domain of IgG prolongs a peptide’s circulation time through several mechanisms. First, 
the Fc domain can endow hybrid proteins with a longer in vivo circulation time through its 
interactions with FcRn. Similar to albumin’s recycling process, FcRn can bind with the Fc 
domain in an acidic endosomal environment to protect the Fc domain from degradation, while 
disassociating from the Fc domain in neutral pH environment outside the cell [68]. The important 
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role played by FcRn in prolonging a peptide half-life was evidenced in Suzuki et al. [69], where 
the affinities of Fc-fusion proteins for FcRn were closely correlated to their half-lives. Fc fusion 
also reduces renal filtration of peptides by increasing their molecular weight, which is especially 
favorable for GLP-1 RAs that are eliminated primarily by the kidney [21]. Fc fusion also reduces 
DPP-4 degradation of GLP-1, likely due to steric hindrance by the bulky IgG fragment  [70]. 
From a technological viewpoint, Fc-fusion to GLP-1 allows for an easier purification process 
relative to albumin fusion due to widely available protein A binding columns used for IgG 
purification [71]. 
An important concern associated with the development of GLP-1 Fc fusion products is their 
potential safety risk arising from the ability of the Fc fragment to trigger antibody-dependent cell-
mediated (ADCC) cytotoxicity and complement-mediated cell lysis through Fc-γ receptor 
interactions. When compared to the IgG1 Fc domain, the IgG2 and IgG4 Fc domains may be 
more favorable in the development of GLP-1 RAs due to their lower affinity for Fc-γ and 
complement receptors [72, 73]. The potency of GLP-1 RA after Fc fusion is another concern, as 
linking the GLP-1 analog with the IgG1 hinge region directly results in a severe loss of potency, 
suggesting a suitable spacer is needed for potency retention [74]. 
The most successful GLP-1 product employing the Fc-fusion strategy is dulaglutide 
(Trulicity®), approved by the FDA in 2014 as an adjunctive therapy for type 2 diabetes. 
Dulaglutide is a disulfide-bonded homodimer fusion peptide with each monomer consisting of 
one GLP-1 analog moiety and one IgG4 Fc region (Fig. 1 and 4). Within the GLP-1 analog, Ala8 
is replaced by Gly to resist DPP-4 degradation, and Gly36 is substituted for Arg to avoid a 
potential T-cell epitope interaction [74]. The IgG4 Fc region was selected and its sequence 
modified at several positions to further reduce its interaction with the Fc-y receptors to avoid 
ADCC immunologic side effects [74]. A spacer comprising 16 amino acids was added between 
the GLP-1 analog and the Fc moiety to prevent activity loss. Dulaglutide has an extended half-
life of 4.7 days, allowing for once weekly dosing. Patients begin therapy with a 0.75 mg/dose 
once weekly (corresponding to 0.024 Pmol GLP-1 RA/dose), and the dose can be doubled for 
additional glycemic control [24]. 
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Figure 4. (A) Half-life extension mechanisms of dulaglutide. (B) FcRn recycling pathway of 
dulaglutide. (C) Mean concentration-time profile of dulaglutide following single dose of 1.5 mg 
subcutaneously injected in abdomen, thigh, or arm. Data obtained from an EMA assessment 
report of Trulicity® [75]. 
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2.6 Sustained-release drug delivery systems  
Another strategy to achieve sustained plasma levels of GLP-1 RAs is by taking advantage 
of drug delivery systems. Various systems including polymeric hydrogels [76], nanoparticles [77] 
and microparticles [78] have been tested in preclinical studies. However, only poly(lactic-co-
glycolic acid) (PLGA) based implants of GLP-1 RA have been approved by the FDA thus far. 
PLGA is well accepted by regulatory authorities as a safe and efficacious way to deliver 
therapeutic peptides. Lupron Depot®, a microsphere formulation of leuprolide acetate and 
Zoladex®, a millicylinder formulation of goserelin, are examples of FDA approved PLGA-based 
sustained release products [79, 80]. In these products, peptides are loaded within a PLGA 
polymer which slowly degrades in the body, allowing for sustained release of the therapeutic 
peptide. For example, Lupron Depot® can release the loaded leuprolide over an extended 
period of 1 or 6 months, depending on the specific polymer formulation used [81]. Such an 
extended release profile enables maintenance of target peptide concentrations with fewer 
administrations, thus improving patient compliance.  
The PLGA delivery approach was applied in the design of a polymer microsphere 
formulation of exenatide in collaboration between Eli Lilly, Amylin and Alkermes [82]. Although 
the degradation of PLGAs can be tuned from a few weeks to more than six months, exenatide 
PLGA microspheres fall short of a more desirable monthly administration, and the final product,  
Exenatide QW (Bydureon®), was launched as a once-a-week product [82]. Once injected 
subcutaneously, the 60-Pm-diameter microspheres hydrate and adhere to each other, forming a 
matrix drug reservoir in situ. A discontinuous drug release profile with a low initial burst and two 
peaks of drug release at the 2nd and 7th week is observed, corresponding to different 
mechanisms of exenatide release from microspheres (Figure 5B) [79]. During the first 48-hour 
“burst release” stage exenatide is released from the surface and surface pores of the 
microspheres. This product was specifically designed to have low initial drug burst in order to 
avoid nausea and vomiting side effects [82]. The second stage is characterized by the slow 
diffusion of exenatide out of the polymer matrix with the maximum diffusion rate and 
corresponding plasma concentration peak achieved at about 2 weeks. The third stage of drug 
release results from the hydrolysis and erosion of the PLGA polymer [82]. The maximum drug-
release rate at this stage is achieved at 7 weeks, which is evidenced by the second peak of the 
blood concentration-time curve. The overall release of exenatide can last for 11 weeks [23]. 
After the first 6-7 weekly administrations of Bydureon®, a stable steady state plasma level of 
exenatide is achieved at 300 pg/ml as peaks and valleys from weekly dosages at different 
injection sites begin to overlap (Figure 5C) [83]. 
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As discussed above, one of the drawbacks of PLGA microparticles in the Bydureon® 
formulation is that they cannot deliver GLP-1 RAs at a steady rate. To address this problem and 
achieve steady and continuous deliver of GLP-1 RAs, other controlled-release devices such as 
osmotic pumps have been developed. One representative product is ITCA 650, developed by 
Intarcia Therapeutics. ITCA 650 is a subcutaneously implanted matchstick-sized osmotic mini-
pump, which continuously releases exenatide for 6 months in a zero-order manner, making 
twice-yearly administration possible [84]. The zero-order release of exenatide results in a 
favorable pharmacokinetic profile of ITCA 650 for several reasons. Pharmacokinetic studies 
showed the ITCA 650 could achieve steady-state exenatide concentration within 5 days 
following implantation, compared to 6-7 weeks for exenatide QW [31]. The plasma 
concentration of exenatide remained steady over the period of treatment [31]. Furthermore, the 
drug treatment can be discontinued if necessary by removal of the implant. In the clinical trials, 
once the implanted pump was removed, exenatide levels became undetectable by 24 hours 
[31]. A New Drug Application for ITCA 650 was submitted to the FDA in November 2016 [85]. If 
approved, it would be the first needle-free GLP-1 RA on the market. 
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Figure 5. (A) Release process of exenatide from microspheres. (B) Mean concentration-time 
profile of exenatide following single dose of Bydureon®. (C) Mean concentration-time profile of 
exenatide following repeated weekly administrations of Bydureon® (exenatide ER same as 
exenatide QW) compared with a single administration of Byetta® (exenatide IR). Adapted with 
permission of © 2011 Adis Data Information BV from Fineman et al. Clin Pharmacokinet 2011; 
50 (1).[83] 
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Figure 6. Schematic of ITCA 650 (A) and mean concentration-time profile of exenatide following 
implantation of ITCA 650 (B). With permission of Henry et al. Clinical therapeutics 35.5 (2013): 634-
645. [86] 
 
2.6 Other approaches for half-life extension 
PEGylation is another common strategy for enhancing in vivo stability of therapeutic 
peptides. PEGylation increases molecular size and provides steric hindrance to reduce renal 
filtration and protect peptide from enzymatic degradation [87]. PEGylated GLP-1 analogs have 
been investigated by several groups. Lee et al. [88] synthesized N-terminally PEGylated 
PEG2k-N-GLP-1 and Lys26- or Lys34-modified PEG2k-Lys-GLP-1s. The in vitro study showed 
that PEG2k-N-GLP-1 exhibited a significant reduction in potency, which is likely due to the steric 
hindrance of PEG shielding the GLP-1 receptor interaction  [88]. PEG2k-Lys-GLP-1, however, 
showed a similar potency to native GLP-1  [88]. Stability studies found that PEG2k-Lys-GLP-1 
was resistant to DPP-4 degradation and had a longer mean retention time in vivo  [88]. One 
PEGylated GLP-1 analog, LY2428757, advanced to clinical testing by Eli Lilly & Co. for once-
weekly administration. To the best of our knowledge, the exact structure of LY2428757 has not 
been disclosed. The Phase 2 clinical trial was completed in 2010 [89], however, no further 
information is available about this product’s development status. As an alternative to PEG, 
XTEN® is a  series of  recombinant protein polymers which are specifically designed for fusion 
to therapeutic peptides to achieve long circulation in vivo [90]. The XTEN-GLP-1 fusion protein, 
VRS-859, was tested in a Phase I clinical trial conducted by Versartis in 2010 as a once monthly 
administration [91]. However, the development of this product has also likely been discontinued. 
 
3. The effects GLP-1 RA delivery strategies on product efficacy and safety 
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Different modification strategies not only affect the pharmacokinetic profiles of GLP-1 RAs 
but also strongly influence their efficacy, safety profile and usability. The main pharmacological 
efficacy biomarkers determined in Phase 3 studies for GLP-1 RAs are summarized in Table 3. 
Based on the pharmacokinetic properties, GLP-1 RAs could be roughly divided into short-acting 
agonists which are administered once or twice daily, and long-acting agonists which are 
administered once weekly. The two groups of GLP-1 RAs, while sharing many similarities, 
present different pharmacodynamic features and, thus, yield different antidiabetic efficacy. 
 
3.1 Glycemic control patterns 
GLP-1 RAs can efficiently regulate plasma glucose levels through multiple mechanisms, 
including stimulation of insulin production, inhibition of glucagon secretion and slowing gastric 
emptying. Though both short-acting and long-acting GLP-1 RAs show favorable glucose control 
efficacy, they have different effects on fasting plasma glucose (FPG) and postprandial plasma 
glucose (PPG) levels. Clinical studies have demonstrated that short-acting GLP-1 RAs have a 
greater efficacy in lowering PPG level, while long-acting GLP-1 RAs predominantly affect FPG 
levels. For example, in a head-to-head clinical trial comparing exenatide BID (Byetta®) and 
exenatide QW (Bydureon®), patients treated with exenatide BID had a lower PPG, while 
patients treated with exenatide QW had a lower FPG [92]. As exenatide was the same active 
ingredient in both groups, this data suggests that PK profile significantly influences 
pharmacological activity of short-acting versus long-acting GLP-1 RAs, resulting in differential 
reduction of PPG and FPG levels. 
It is believed that a product’s effect on FPG level is directly related to pharmacokinetics of 
GLP-1 RA and GLP-1 receptor activation pattern, which, in turn, leads to the differential 
secretion of insulin and glucagon during a fasting state [93]. Short-acting GLP-1 RAs usually 
have limited drug exposure within the body due to rapid elimination. Exenatide, for example, 
administered one hour before the morning and evening meal, is almost completely eliminated 
from the plasma after 10 hours [94]. Thus, the GLP-1 plasma concentration in the middle of the 
day and overnight is low, leading to modest efficacy on FPG regulation. On the contrary, long-
acting GLP-1 RAs that are present in the circulation between injections enables sustained GLP-
1 receptor activation and continuous stimulation of insulin secretion. In the clinical trial 
comparing exenatide BID (Byetta®) and liraglutide (Victoza®), the fasting insulin level of the 
Victoza®-treated group increased on average by 12.43 pmol/L, while that of Byetta® decreased 
by 1.38 pmol/L [95]. Increased insulin secretion during a fasting state was also observed for 
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other long-acting GLP-1 RAs such as dulaglutide (Trulicity®) [96] and albiglutide (Tanzeum®) 
[97]. 
The efficacy of GLP-1 RAs on PPG, however, is thought to primarily result from delayed 
gastric emptying rather than stimulation of insulin production [98]. An inverse relationship 
between gastric emptying rate and PPG has been demonstrated in clinical trials [99, 100]. 
Short-acting GLP-1 RAs such as exenatide BID (Byetta®) and lixisenatide (Adlyxin®) can 
significantly delay gastric emptying processes in vivo. The delayed gastric emptying leads to the 
reduced plasma glucose excursion. As a result, postprandial insulin concentrations are actually 
dose-dependently decreased, by exenatide and lixisenatide despite the known ability of GLP-1 
RAs to stimulate insulin production [99, 100]. On the other hand, long-acting GLP-1 RAs have 
only a modest effect on gastric emptying, possibly caused by tachyphylaxis due to continuous 
activation of the GLP-1 receptor [101, 102]. For example, in a clinical study comparing 
exenatide BID (Byetta®) and exenatide QW (Bydureon®), it was found that after 14 weeks of 
administration, Byetta® still induced significant retardation of gastric emptying, while Bydureon® 
had little effect on gastric mobility [92]. Consequently, long-acting GLP-1 RAs typically lead to 
less profound reductions of PPG compared to short-acting GLP-1 RAs [98].  
 
3.2 Impact of various GLP-1 RAs on glycated hemoglobin (HbA1c) levels  
Glycated hemoglobin (HbA1c) is a biomarker extensively used by diabetologists to evaluate 
the ability of patients to control overall blood sugar level over periods of weeks to months. The 
higher the HbA1c level, the worse a patient’s glycemic control and the higher the likelihood that 
that individual will develop diabetes-related complications [103]. All commercialized GLP-1 RAs 
have proved to effectively reduce levels of HbA1c (Table 3). Though directly comparing the 
HbA1c reduction of different GLP-1 RAs is challenging, several head-to-head clinical studies 
have provided insight into differences between these products [104]. Compared with short-
acting products, long-acting GLP-1 RAs usually present better efficacy in reducing HbA1c, 
which may result from their ability to better control FPG levels. The DURATION-1 and 
DURATION-5 clinical trials, which directly compared exenatide BID (Byetta®) to exenatide QW 
(Bydureon®), reported better HbA1c level reduction for Bydureon® [105, 106]. Another clinical 
trial, LEAD-6, showed greater reduction of HbA1c levels in patients treated with long-acting 
Victoza® relative to short-acting Byetta® (-1.12% versus -0.79%, p < 0.0001) [95]. Similarly, 
dulaglutide (Trulicity®) reduced HbA1c levels more effectively than exenatide twice daily 
(Byetta®) in the AWARD-1 trial (-1.51% for dulaglutide 1.5 mg, -1.30% for dulaglutide 0.75 mg 
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versus -0.99% for exenatide twice daily, p < 0.001 for both dulaglutide groups relative to 
exenatide) [107]. 
Differences in efficacy among GLP-1 RAs belonging to the same class seem less 
significant. No statistically significant differences were found between the short-acting 
compounds Byetta® and Adlyxin® in the head-to-head GetGoal-X trial [42]. Among long-acting 
GLP-1 RAs, the HbA1c-reduction efficacy of Victoza® (liraglutide) was not significantly different 
from that of Trulicity® (dulaglutide) [107] or Tanzeum® (albiglutide) [108]. The DURATION-6 
trial demonstrated that Victoza® showed greater reduction of HbA1c levels than Bydureon® 
[109]. However, additional retrospective meta-analyses of various clinical data sets found no 
meaningful difference in HbA1c reduction between Victoza® and Bydureon® [110-112]. 
 
3.3 Weight loss  
GLP-1 receptor activation may lead to significant weight loss by suppressing appetite, thus 
reducing calorie intake [113]. Though delayed gastric emptying and GI side effects of GLP-1 
RAs are tempting explanations for the weight loss, their correlation with weight loss in diabetic 
patients was contradicted by several clinical trials [114, 115]. Instead, the anorectic effect of 
GLP-1 RAs was found to be responsible for the weight loss, which is mainly attributed to the 
satiating effect or rapid hunger satisfaction after the start of a meal. This effect is a result of 
peripheral and central GLP-1 receptor activation, and is afforded by the ability of GLP-1 RAs to 
cross the blood brain barrier (BBB) [116]. In one study, vagal deafferentation attenuated the 
anorectic effects of exendin-4 and liraglutide [116]. Another recent study showed that liraglutide 
can activate the GLP-1 receptor on appetite-regulating neurons in the arcuate nucleus (ARC), 
which may mediate its long-term weight loss effects[117]. Collectively, GLP-1 RAs show varied 
effects on weight loss, which may result from multiple factors. For example, unlike liraglutide, 
clinical studies with albiglutide resulted in little weight loss, potentially attributed to limited 
penetration of the large molecular weight of albumin fusion proteins into the central nervous 
system, the major site of action [118]. 
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Table 3. Summary of GLP-1 RA initial therapy and monotherapy Phase 3 clinical trials. 
 
Abbreviations: FPG: fasting plasma glucose level; PPG: postprandial plasma glucose level; HbA1c: level 
of hemoglobin A1c; BID: twice a day; QW: once a week; N. A.: information is not available.  
 
3.4 GLP-1 RA safety issues  
The most frequently-observed side effects of GLP-1 RAs are gastrointestinal in nature, 
including nausea, diarrhea and vomiting. Nausea is the most commonly-reported adverse effect, 
though it usually decreases over time as a patient’s tolerance toward GLP-1 administration 
increases [125]. Nausea directly correlates with plasma levels of GLP-1 RAs and, thus, is more 
profound in short-acting GLP-1 RA products relative to long-acting GLP-1 RAs due to high peak 
peptide plasma concentration and large peak-to-through ratios [126]. For example, in several 
clinical studies, between 33% and 57% patients treated with exenatide [127] and between 24% 
and 76% of patients treated with lixisenatide [42, 120, 128-134] reported nausea. In contrast, 
GLP-1 RAs Dose FPG (mg/dl) 
PPG 
(mg/dl) 
HbA1c 
(%) 
Weight 
loss (kg) References 
Exenatide BID 
(Byetta®) 10 Pg BID -18.7 -24.7 -0.9 -3.1 [119] 
Lixisenatide 
(Lyxumia®/ 
Adlyxin®) 
10 Pg for 2 wks 
then 20 Pg -19.8 -98.5 -0.85 -2 [120] 
10 Pg for wk 1, 
15 Pg for wk 2, 
then 20 Pg 
-16.2 -81.2 -0.73 -2 [120] 
Liraglutide 
(Victoza®) 
1.2 mg -14.4 -30.6 -0.84 -2.1 [121] 
1.8 mg -25.2 -37.8 -1.14 -2.5 [121] 
Semaglutide 
(Ozempic®) 
0.5 mg -45 N. A. -1.45 -3.7 
[59] 
1.0 mg -41.4 N. A. -1.55 -4.53 
Dulaglutide 
(Trulicity®) 
0.75 mg -26 -41.4 -0.71 -2.36 [122] 
1.5 mg -29 -43.4 -0.78 -2.29 [122] 
Albiglutide 
(Tanzeum®/ 
Eperzan®) 
30 mg -34 N. A. -0.84 -0.4 [123] 
50 mg -43 N. A. -1.04 -0.9 [123] 
Exenatide QW 
(Bydureon®) 2 mg -41.4 N. A. -1.53 -2.0 [124] 
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only 9.9% to 16% patients treated with albiglutide [108, 123, 135-138] and 6.6% to 28% of 
patients treated with dulaglutide [107, 122, 139-142] experienced nausea. In a head-to-head 
clinical trial comparing exenatide BID (Byetta®) and exenatide QW (Bydureon®), the incidence 
of nausea in patients treated with Byetta® was 35% compared to 14% in those treated with 
Bydureon® [105]. This difference could be explained by the decreased fluctuation of plasma-
drug concentrations seen with long-acting products, particularly the avoidance of the high peak 
concentrations seen with GLP-1 RAs [105].  
Injection site reactions are another common side effect of GLP-1 RAs. The incidence of 
injection site reactions differs among GLP-1 RAs with different molecular structures. For short-
acting GLP-1 RAs, such as Byetta®, Victoza® and Adlyxin®, the incidence of injection site 
reactions is relatively low (< 5%) [107, 109, 120, 128, 134, 143]. For long-acting GLP-1 RAs, 8% 
to 16% patients treated with Tanzeum® had injection site reactions [108, 123, 135-138]. In 
addition, less than 5% of patients treated with Trulicity® experienced injection site reactions 
[107, 122, 139-142]. Formulation factors also affect the incidence of injection site reactions. 
Bydureon® administration leads to a higher incidence of injection site reactions compared to 
Byetta® [144]. Particularly, injection of Bydureon® can cause a bump at the injection site and 
local inflammatory response, which may lead to discontinuation of the drug [92, 145]. 
Development of anti-drug antibodies is a common concern with therapeutic peptides and 
proteins. For GLP-1 RAs, exenatide seems to have the highest incidence of antibody formation, 
which be due to its relatively low homology to human GLP-1 (53%). About 37% of patients 
treated with Byetta® and 57% patients treated with Bydureon® tested positively for the 
presence of anti-drug antibodies [144]. While low titers of the antibody have little impact on the 
drug’s efficacy and safety profiles, high titers may reduce the efficacy of exenatide [144]. For 
comparison, only 8.6% of patients treated with liraglutide generated antibodies, which can be 
explained by the higher sequence homology with GLP-1 [146]. Incidence of anti-drug antibodies 
was much lower for albiglutide and dulaglutide. In Phase 3 clinical trials, anti-drug antibodies 
were detected in 3.0% to 7.0% of patients treated with albiglutide [108, 132, 135, 147, 148] and 
2.2% of patients treated with dulaglutide [122]. In both cases, the presence of anti-drug 
antibodies was not correlated with relevant hypersensitivity events. 
There are also concerns that long-term usage of GLP-1 RAs may cause pancreatitis or 
even lead to the development of pancreatic cancer. In a mouse study, exendin-4 induced 
pancreatic duct gland expansion in rats and exacerbated chronic pancreatitis [149]. Elashoff et 
al. analyzed data from the FDA database and found that patients treated with exenatide had a 
6-fold higher incidence of pancreatitis compared to those treated with other diabetes 
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medications, such as rosiglitazone, nateglinide, repaglinide and glipizide [150]. However, in the 
studies directly conducted by the FDA, no correlation between exenatide and pancreatic injury 
was found in animal models, and no compelling evidence was found to link the use of exenatide 
with an increased risk of pancreatitis or pancreatic cancer [151]. Because of these inconsistent 
results, no final conclusion has been made regarding correlations between exenatide use and 
serious adverse pancreatic events [151]. 
Liraglutide was found to be associated with thyroid cancer in rodents. Further studies found 
that long-term activation of GLP-1 receptors could stimulate calcitonin secretion and induce C-
cell hyperplasia, which increases the incidence of medullary thyroid cancer in mice [152]. Such 
observations raise safety concerns about GLP-1 RAs. However, in humans, liraglutide was 
found to have no significant effect on calcitonin secretion [153]. In a meta-analysis, no 
correlation was found between liraglutide and an increased risk for thyroid cancer [154]. Thus, 
the correlation between GLP-1 RAs and thyroid cancer is not yet clear. However, based on 
these results, liraglutide is contraindicated in patients with a history of medullary thyroid cancer. 
 
4. Combination treatments 
Because of the complex pathological processes of type 2 diabetes, optimal glucose control 
typically requires multifaceted therapeutic strategies. The combination of GLP-1 RAs and basal 
insulin is frequently used because of the complementary effects of both agents on glucose 
control. Basal insulin consistently increases insulin levels and lowers FPG. Meanwhile, GLP-1 
RAs stimulate insulin secretion in a glucose-dependent manner which provides better control 
over PPG. Also, adding GLP-1 RAs could counteract the hypoglycemia and weight gain 
frequently resulting from insulin therapy [155]. However, in clinical practice, healthcare providers 
may find it challenging to adjust the dose of each drug in combination to achieve optimal 
glucose control while avoiding side effects, hindering the practical application of combination 
therapy. To address this problem and to gain market advantage, pharmaceutical companies 
have developed various combination therapy products for type 2 diabetes. Novo Nordisk 
developed an insulin degludec/liraglutide combination named Xultophy® 100/3.6, or IdegLira 
[28]. Sanofi developed titratable lixisenatide and insulin glargine combination SOLIQUA® 
100/33 (also named LixiLan or IGlarLixi) with a fixed ratio of 100 Units/mL lixisenatide to 33 
mcg/mL insulin glargine [29]. Both Xultophy® and SOLIQUA® were approved by the FDA in 
November 2016.  
It is noteworthy that although GLP-1 and insulin combination therapy may provide 
convenience in practice, combination therapy comes at the cost of diminished dosing flexibility 
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of both drugs, raising concerns about whether the specific combination therapy actually 
achieves better therapeutic efficacy than two drugs that are titrated separately. To prove the 
superiority of the combination therapies, clinical trials were designed to test whether the 
combination has a superior efficacy over monotherapy. The Xultophy® DUALTM Phase 3 clinical 
trials showed combination therapy leads to greater HbA1c decrease and weight loss compared 
to insulin monotherapy [156]. As for SOLIQUA®, the clinical trial showed that a larger proportion 
of patients reached H1A1c target levels compared to patients treated with insulin alone [157]. 
 
5. GLP-1 RA market dominance analysis 
Pharmaceutical sales are affected by a variety of factors, including product efficacy, safety 
and the ability to fulfill an unmet need within the target therapeutic area. Other factors such as 
first-to-market, patent exclusivity status, marketing strategy, product pricing and government 
price controls, and geography of drug approval also have a substantial impact on total sales and 
ultimate market share. In the context of the diabetes therapeutic market, other points to consider 
are country specific disease treatment guidelines and pricing/reimbursement decisions [158, 
159]. While it can be difficult to predict which factors will be most relevant in affecting 
commercial success from one product to the next, it is possible to observe sales trends and 
make pharmacoeconomic assessments within the current global GLP-1 market. Figure 7 and 
Table 4 show market shares of GLP-1 RA products in 2016 and 2017. The figure illustrates the 
overall market dominance of Victoza®, growing market share of Trulicity® and steady presence 
of Bydureon®. The rest of the market was shared by Byetta®, Tanzeum®, and Adlyxin®.  
Byetta® was first launched in the U.S. in 2005 and was the only GLP-1 RA on the market 
until the approval of Victoza® in 2010. The drug reached $678.5 million peak sales in 2008. 
Despite the overall growth in the diabetes market, sales of Byetta® steadily declined to $254 
million (5.1% market share) in 2016 and $176 (2.7% market share) in 2017 (Figure 7, Table 4) 
due to competition from other safer and more convenient GLP-1 RAs. Byetta® is expected to 
lose patent protection soon, and a generic injectable exenatide has been filed with the FDA 
[160]. Introduction of generic versions of Byetta® could affect the market, as generic drugs 
provide cheaper treatment alternatives preferable to patients, prescribers, and payers [161]. The 
introduction of low-price GLP-1 RA generics will certainly change sales dynamics and 
prescribing habits, especially within healthcare systems under financial scrutiny.  
A more convenient once-daily dose product, Victoza®, was introduced into the U.S. market 
in 2010 by Novo Nordisk. Victoza® is supplied in an easy-to-use self-injector and offers 
therapeutic efficacy similar to Byetta® but with a reduction in side effects [95]. Victoza® 
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immediately gained market share with 2011 sales of $1,289.7 million relative to $517.7 million 
for Byetta® [162, 163]. Over the years Victoza® has continued its growth and market 
dominance with global sales reaching $3376 million in 2017, capturing over 50% of the overall 
GLP-1 market share. Based on positive clinical trial results, Novo Nordisk recently received 
approval from the FDA to add a new indication to Victoza®: lowering cardiovascular risks in type 
2 diabetes patients with established cardiovascular disease [164]. This addition makes Victoza® 
the only GLP-1 RA product approved for a cardiovascular indication. Similarly, an alternative 
dosage form of liraglutide, Saxenda®, was recently approved to treat obesity [165], and is 
currently the only GLP-1 RA approved in for this indication. Another strategy to maintain market 
dominance is to seek approval for combination therapies in a single injection. Thus, Xultophy®, 
a combination of liraglutide and insulin-degludec, was developed by Novo Nordisk. However, 
the sales of Xultophy® were relatively small in 2017 (just $106 million or 1.6% of GLP-1 RA 
market share) [166]. 
Amylin, a company initially developing exenatide, focused on the design of a PLGA polymer 
extended release formulation of exenatide in partnership with Alkermes. While for peptides like 
leuprolide, PLGA delivery offers once-monthly to once every six months products, the exenatide 
PLGA implant formulation, Bydureon®, was launched as a once- weekly product due to 
discontinuous release of peptide from the polymer and a narrow therapeutic index. Despite 
robust efficacy and being the first once-weekly formulation to reach the market, sales of 
Bydureon® fell short of expectation. In 2013, Bydureon® world-wide sales were a mere $151 
million, significantly lower than that of twice daily injections of Byetta® ($206 million) and once-
daily Victoza® ($2,035 million) [167, 168]. Inadequate sales of Bydureon® could be attributed to 
Bydureon®’s failure to show non-inferiority compared to Victoza® in the DURATION-6 trial 
[109]. Another possibility is the difficulty for some patients to create a suspension and self-
administer the polymer microspheres [23]. Knowing that the multistep process for injection may 
hinder patient compliance, AstraZeneca designed a new, easy-to-use Bydureon® pre-filled pen, 
called Bydureon  BCise™ [169]. In addition, injection site side effects were reported for 
Bydureon® including local inflammation, abscess formation and cosmetic concerns due to 
retention of “bumps” under the skin that remain for extended periods of time due to the long time 
required for polymer degradation [145].  Despite these concerns the sales of Bydureon® 
remained steady at ~$570 million in 2016 and 2017 and could further improve with the launch 
Bydureon  BCise™ in 2018. 
Great expectations were associated with the launch of easy-to-administer solutions of once-
weekly GLP-1 RA products: albumin fusion (Tanzeum®) and Fc-fusion (Trulicity®). Interestingly, 
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upon launch, Tanzeum® did not capture a significant market share. Its sales were only $63 
million in 2015 as compared to $2.673 billion in sales for Victoza® that same year [170, 171]. 
Weak sales could be attributed to the increased immunogenicity and reduced therapeutic 
benefit offered by Tanzeum®, with efficacy parameters trailing behind Victoza® [108]. In 
addition, the relative inexperience of GSK in marketing diabetes drugs may have contributed to 
the poor sales. To improve sluggish sales, GSK tried to lower prices of Tanzeum®.  Yet, 
Tanzeum® still failed to be listed as a preferred formulary by PBM Express Scripts [172]. Due to 
the continuous decline in sales, GSK chose to cease manufacturing and sale of Tanzeum® by 
July 2017 [173]. 
In contrast, once weekly Trulicity® launched by Eli Lilly in the same time frame did gain 
rapid acceptance. When compared with Victoza®, Trulicity® offered a similar therapeutic benefit 
and showed even better control over HbA1c levels in the AWARD-6 clinical trial [107]. Eli Lilly 
also had a large existing sales force in diabetes due to its insulin franchise, which likely 
facilitated successful product launch. Trulicity® sales in 2015 reached $248.7 million and 
continued to climb to $925.5 million in 2016 and to $2030 million in 2017, taking significant 
market share away from Victoza® (Figure 7, Table 4) [174-176]. Based on 2016 sales, Victoza® 
dominated the GLP-1 RAs with 60.0% market share followed by Trulicity® with 18.6%. In 2017, 
Trulicity  gained a spot on Express Scripts’ preferred formulary for the second year in a row, 
while Victoza® did not [172]. This designation was expected to further boost Trulicity® sales. In 
2017, the growth of Trulicity  continued as Victoza ’s market share dropped to 52.2% and 
Trulicity ’s rose to 31.6%. While the main competition will likely remain between Victoza® and 
Trulicity®, several developments could impact the market, such as introduction of generic 
versions of Byetta® and approval of Ozempic®. Ozempic® is expected to be the next  
blockbuster on the GLP-1 market due to its excellent anti-diabetes efficacy [59], substantial 
reduction of cardiovascular risks [177] and once-weekly dosing frequency. Thus, it would be 
interesting to see how the landscape of the growing GLP-1 RA market will change over the next 
several years.   
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Figure 7. Market share of GLP-1 RAs in 2016 and 2017. 
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 Table 4. G
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As in 2016 and first six m
onths of 2017.  
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2016 Sales (in 
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SD
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illions) 
2017 Sales (in U
SD
, 
m
illions) 
M
arket Share 
2016 (%
) 
M
arket Share 
2017 (%
) 
AstraZeneca 
B
yetta®
 
Exenatide 
254 [178] 
176 [179] 
5.1 
2.7 
AstraZeneca 
B
ydureon®
 
Exenatide 
(extended-release) 
578 [178] 
574 [179] 
11.6 
8.9 
N
ovo N
ordisk 
Victoza®
 
Liraglutide 
2977 [180] 
3376 [166]* 
60.0 
52.5 
N
ovo N
ordisk 
X
ultophy®
 
100/3.6 
Liraglutide/ 
insulin-degludec 
30 [166]* 
106 [166]* 
0.6 
1.6 
G
laxoSm
ithK
line 
Tanzeum
®
/ 
Eperzan®
 
Albiglutide 
165 [181]* 
 108 [182]* 
3.3 
1.7 
Eli Lilly & C
o 
Trulicity®
 
D
ulaglutide 
926 [174] 
2030 [176] 
18.6 
31.6 
Sanofi 
Lyxum
ia®
/ 
Adlyxin®
 
Lixisenatide 
36 [183]* 
28 [184]* 
0.7 
0.4 
Sanofi 
Soliqua® 
100/33 
Lixisenatide/Insulin 
N
/A
 
 28 [184]* 
N
/A
 
0.4 
*A
ll sales used to calculate m
arket share w
hich w
ere not reported in U
SD
 w
ere first converted to U
SD
 using 2016 yearly average currency 
exchange rates or 2017 yearly average currency exchange rates respectively. M
arket shares calculated using publicly-reported full-year sales for 
2016 and 2017 based on proportion of U
SD
 earned in total global sales.  
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6. Emerging trends in GLP-1 RA development 
Despite the large number of GLP-1 RAs already approved, there are numerous ongoing 
efforts to develop new GLP-1 RA molecules as well as explore novel routes of administration. 
Oral products have better patient compliance relative to subcutaneous injectable products, as 
some patients have a fear or injection  [185, 186]. Another challenge for subcutaneous injection 
products is the difficulty of administration for patients suffering with visual or motor skill 
impairment, common ailments for patients with type 2 diabetes [187]. To address these issues, 
two orally available GLP-1 RAs are currently in clinical trials. A once-daily oral semaglutide is 
being developed by Novo Nordisk. The oral delivery of semaglutide is achieved by using the 
Eligen® technique developed by Emisphere Technologies. Semaglutide is co-formulated with 
sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), a delivery carrier to enhance 
gastrointestinal absorption [188]. SNAC can non-covalently interact with peptide, forming a 
peptide/SNAC complex with increased lipophilicity able to permeate through the gastrointestinal 
epithelium via transcellular pathways [189]. The efficacy of different doses of oral semaglutide 
(2.5 mg, 5 mg, 10 mg, 20 mg and 40 mg once daily) were assessed and compared to 
subcutaneously delivered semaglutide (1 mg/dose once weekly) in Phase 2 clinical trials. 
Although percent semaglutide bioavailability is in single digit [190], the efficacies of either the 20 
mg or 40 mg once daily oral doses of semaglutide were comparable to the 1 mg once weekly 
dose of drug administered subcutaneously [191]. Additionally, a dose-dependent HbA1c 
reduction ranging from −0.7% to −1.9% and body weight loss ranging from −2.1 kg to −6.9 kg 
was found [191, 192]. Oral semaglutide is currently being tested in the Phase 3 trial (PIONEER) 
in type 2 diabetes patients [193]. Another oral GLP-1 RA product, ORMD-0901, developed by 
Oramed, was tested in Phase 2 clinical trials [194]. Here, oral delivery is achieved by using 
PODTM technology where exenatide is encapsulated into coated capsules with protease 
inhibitors and absorption enhancers [195]. However, there have been no recent updates nor 
published efficacy data regarding this investigational drug.  
Other delivery routes for GLP-1 RAs have also been investigated. Mannkind Corporation 
recently developed a GLP-1 inhalation powder, MKC253, for pulmonary delivery based on the 
TechnosphereTM technique [196]. In this method, GLP-1 is absorbed onto TechnosphereTM 
microparticles composed of fumaryl diketopiperazine (FDKP) with a size range of 2-5 Pm. Once 
the GLP-1 loaded microspheres arrive at the lung, FDKP dissolves and GLP-1 is absorbed into 
systemic circulation [196]. In a phase 1 clinical study, peak concentrations of GLP-1 were 
achieved within 5 min, and GLP-1 was eliminated after 30 minutes with an estimated 
bioavailability between 0.5% to 1.6% [197]. TransPharma Medical Ltd developed a transdermal 
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delivery system for their GLP-1 agonist ViaDor-GLP1, achieved using a hand-held 
microporation-based device, and have completed a Phase 1 clinical trial [198]. Based on the 
available data, the long-term success of these oral, inhalable or transdermal GLP-1 RAs 
remains unclear. Several non-invasive approaches have been developed in the past for insulin 
delivery [199, 200], but many of these products, particularly oral insulin products, faced 
challenges in clinical trials due to variable therapeutic responses owing to patient-to-patient 
differences in bioavailability [201-203]. Others, such as Exubera® (inhaled insulin) failed due to 
poor market penetration as well as safety concerns associated with drug accumulation in the 
lungs [204, 205]. 
Recently, co-agonists simultaneously activating GLP-1 and other incretin receptors have 
generated significant interest in the pharmaceutical industry. These dual agonists could 
simultaneously exert the functions of GLP-1 and other incretins such as glucagon [206, 207], 
gastric inhibitory polypeptide (GIP) [208] and gastrin [209], enabling better anti-diabetes 
efficacy. Although using glucagon as a therapy for diabetes seems counterintuitive, GLP-
1/glucagon co-agonists have been reported to produce favorable effects with respect to body 
weight loss and glucose control in animal models [210]. For example, MEDI0382, one GLP-
1/glucagon co-agonist developed by MedImmune, was reported to have glucose-lowering 
efficacy comparable to liraglutide and led to greater weight loss in mice [211]. Major 
pharmaceutical companies, including Novo Nordisk, Sanofi, Eli Lily, Janssen and Merck are 
currently developing their own GLP-1/glucagon co-agonist candidates, most of which are in 
Phase 1 or Phase 2 clinical trials [212]. Other combinations, such as GLP-1/gastrin co-agonists 
and GLP-1/GIP co-agonists, are also under development. One example, a GLP-1/gastrin dual 
agonist developed by Zealand Pharma, is reported to improve glucose control in diabetic mice 
by improving pancreatic E-cell function [213]. As many of these products are peptides, similar 
half-life extension strategies as were used for GLP-1 products will likely be employed in their 
design.  
 
7. Summary 
Here, we presented a case study of the various drug delivery strategies that have been 
applied to extend circulation the half-life of labile GLP-1 peptides. Simple amino acid 
substitutions or sequence modifications of the endogenous GLP-1 to avoid proteolysis lead to a 
modest increase in GLP-1 RA half-life from 2 min to 2-3 hours, resulting in the twice- and once-
daily products Byetta® and Adlyxin®, respectively. However, side effects and reduced efficacy 
associated with high peak to trough ratios in their pharmacokinetic profiles resulted in only 
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limited commercial success of these products, with 2.7 and 0.4% market share for Byetta® and 
Adlyxin®, respectively. When sequence modification was combined with the conjugation of fatty 
acid to allow for slow absorption of peptide and endogenous albumin binding, the plasma 
residence time increased and half-life was extended to 13 hours. Victoza® offers both 
convenience of dosing, robust activity, proven efficacy in cardiovascular event protection and 
reduced side effects relative to Byetta®. In addition, Victoza® was the first product on the 
market to achieve once-daily dosing and was launched by Novo Nordisk, a company 
experienced in diabetes product sales due to its large insulin franchise. These factors 
contributed strongly to development of the most commercially successful GLP-1 RA product, 
Victoza®, earning last year ~$3.4 billion and controlling over 50% of the overall GLP-1 RA 
market.  
To mount competition to Victoza®, four once-weekly GLP-1 RA products were designed. 
Fusion of peptide to either antibody Fc fragment or albumin resulted in the development of 
Trulicity® and Tanzeum®, both with a plasma half-life of 5 days. To improve on Victoza® 
performance, Novo Nordisk developed Ozempic® by modifying the peptide with a longer steric 
fatty di-acid, resulting in a plasma half-life of 7 days. Finally, a polymer-controlled release 
formulation of exenatide, Bydureon®, was developed for once-weekly administration. 
Interestingly, while the clinical efficacy parameters for all weekly products are similar, variations 
in side effect profiles and ease of use between the products have contributed to vastly different 
market penetration. While Bydureon® sales hold steady at ~ 10% of the market, Trulicity® sales 
took off rapidly following product introduction, exceeding 30% of the market share in 2017. In 
contrast, Tanzeum® was unable to capture any market and was discontinued in 2017. The 2018 
market introduction of both potent and easy to use once-weekly Ozempic® will likely again alter 
the GLP-1 RA prescribing landscape. Overall, competition between various peptide delivery 
technologies for capture of GLP-1 RA market represents an interesting case study broadly 
applicable to the development of delivery systems for other peptides and proteins. As scientists 
in the drug delivery field we often focus on engineering products for maximizing plasma half-life 
and investigating mechanisms to achieve it. In that regard, actual market dominance appears to 
be significantly driven by simplicity of use, dosing schedule, injection site discomfort, robust 
efficacy, indication and contraindication in certain subpopulations, and low side-effect profile 
along with non-scientific factors, such as first-to-market, size and experience of the company’s 
diabetes sales force, negotiated pricing and reimbursement agreement, geographic areas of 
regulatory approvals and patent exclusivity. Understanding the entire product landscape is thus 
important in order to maximize product success. 
36 
 
 
8. Acknowledgements 
This work was supported by NIH HL134569 and Amneal Pharmaceuticals grant to A. 
Schwendeman. Emily E. Morin was supported by NIH T32 GM008353 and T32 HL125242. 
 
References 
[1] B.I.D.F. Brussels, International Diabetes Federation. IDF Diabetes Atlas, 8th edn., 2017. 
[2] (!!! INVALID CITATION !!! [2]). 
[3] G. International Diabetes Federation Guideline Development, Global guideline for type 2 
diabetes, Diabetes research and clinical practice, 104 (2014) 1-52. 
[4] M.K. Ali, K.M. Bullard, E.W. Gregg, Achievement of goals in U.S. Diabetes Care, 1999-2010, 
The New England journal of medicine, 369 (2013) 287-288. 
[5] (!!! INVALID CITATION !!! [5, 6]). 
[6] (!!! INVALID CITATION !!! [6, 7]). 
[7] J.J. Holst, The physiology of glucagon-like peptide 1, Physiol Rev, 87 (2007) 1409-1439. 
[8] R.M. Elliott, L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright, V. Marks, Glucagon-like 
peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response 
to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns, The Journal of 
endocrinology, 138 (1993) 159-166. 
[9] E. Franek, G. Gajos, J. Gumprecht, A. Kretowski, B. Zahorska-Markiewicz, M.T. Malecki, 
The role of glucagon-like peptide 1 in glucose homeostasis and in other aspects of human 
physiology, Pol Arch Med Wewn, 119 (2009) 743-751. 
[10] A.R. Meloni, M.B. DeYoung, C. Lowe, D.G. Parkes, GLP-1 receptor activated insulin 
secretion from pancreatic beta-cells: mechanism and glucose dependence, Diabetes, obesity & 
metabolism, 15 (2013) 15-27. 
[11] L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP, Gastroenterology, 132 
(2007) 2131-2157. 
[12] Y.Z. De Marinis, A. Salehi, C.E. Ward, Q. Zhang, F. Abdulkader, M. Bengtsson, O. Braha, 
M. Braun, R. Ramracheya, S. Amisten, A.M. Habib, Y. Moritoh, E. Zhang, F. Reimann, A. 
Rosengren, T. Shibasaki, F. Gribble, E. Renstrom, S. Seino, L. Eliasson, P. Rorsman, GLP-1 
inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type 
Ca2+ channel-dependent exocytosis, Cell Metab, 11 (2010) 543-553. 
[13] Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, D.J. Drucker, Glucagon-like peptide-1 
receptor signaling modulates beta cell apoptosis, The Journal of biological chemistry, 278 
(2003) 471-478. 
[14] B. Yusta, L.L. Baggio, J.L. Estall, J.A. Koehler, D.P. Holland, H. Li, D. Pipeleers, Z. Ling, 
D.J. Drucker, GLP-1 receptor activation improves beta cell function and survival following 
induction of endoplasmic reticulum stress, Cell Metab, 4 (2006) 391-406. 
[15] A. Flint, A. Raben, A.K. Ersboll, J.J. Holst, A. Astrup, The effect of physiological levels of 
glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in 
obesity, Int J Obes Relat Metab Disord, 25 (2001) 781-792. 
[16] J.M. Wishart, M. Horowitz, H.A. Morris, K.L. Jones, M.A. Nauck, Relation between gastric 
emptying of glucose and plasma concentrations of glucagon-like peptide-1, Peptides, 19 (1998) 
1049-1053. 
[17] M.D. Turton, D. O'Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. 
Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, S.R. 
Bloom, A role for glucagon-like peptide-1 in the central regulation of feeding, Nature, 379 (1996) 
69-72. 
37 
 
[18] E. Naslund, B. Barkeling, N. King, M. Gutniak, J.E. Blundell, J.J. Holst, S. Rossner, P.M. 
Hellstrom, Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in 
obese men, Int J Obes Relat Metab Disord, 23 (1999) 304-311. 
[19] T. Vilsboll, H. Agerso, T. Krarup, J.J. Holst, Similar elimination rates of glucagon-like 
peptide-1 in obese type 2 diabetic patients and healthy subjects, The Journal of clinical 
endocrinology and metabolism, 88 (2003) 220-224. 
[20] T.J. Kieffer, C.H. McIntosh, R.A. Pederson, Degradation of glucose-dependent 
insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl 
peptidase IV, Endocrinology, 136 (1995) 3585-3596. 
[21] Byetta® (exenatide) injection [prescribing information]. Wilmington, DE: AstraZeneca 
Pharmaceuticals LP; 2015. 
[22] Victoza® (liraglutide) injection, solution for subcutaneous use [prescribing information]. 
Denmark: Novo Nordisk A/S; 2016. 
[23] Bydureon®(exenatide sustained-release) for injectable suspension [prescribing 
information]. Wilmington, DE: Astrazeneca Pharmaceuticals LP; 2015. 
[24] Tanzeum® (albiglutide) for injection, for subcutaneous use [prescribing information]. 
Wilmington, DE: GlaxoSmithKline LLC; 2016. 
[25] Trulicity® (dulaglutide) injection, for subcutaneous use [prescribing information]. 
Indianapolis, IN: Eli Lilly and Company; 2017. 
[26] Adlyxin® (lixisenatide) injection, for subcutaneous use [prescribing information]. 
Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2016. 
[27] OZEMPIC® (semaglutide) injection, for subcutaneous use [prescribing information]. 
Denmark: Novo Nordisk A/S; 2017. 
[28] Xultophy® 100/3.6 (insulin degludec and liraglutide injection) [prescribing information]. 
Bagsvaerd, Denmark: Novo Nordisk A/S; 2016. 
[29] SOLIQUA™ 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use 
[prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2016. 
[30] L. Jensen, H. Helleberg, A. Roffel, J.J. van Lier, I. Bjornsdottir, P.J. Pedersen, E. Rowe, J. 
Derving Karsbol, M.L. Pedersen, Absorption, metabolism and excretion of the GLP-1 analogue 
semaglutide in humans and nonclinical species, European journal of pharmaceutical sciences : 
official journal of the European Federation for Pharmaceutical Sciences, 104 (2017) 31-41. 
[31] R.R. Henry, D. Logan, T. Alessi, M.A. Baron, A Randomized, Open-Label, Multicenter, 4-
Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With 
Type 2 Diabetes, Clinical therapeutics, 35 (2013) 634-645. 
[32] K. Adelhorst, B.B. Hedegaard, L.B. Knudsen, O. Kirk, Structure-activity studies of glucagon-
like peptide-1, The Journal of biological chemistry, 269 (1994) 6275-6278. 
[33] C.F. Deacon, Circulation and degradation of GIP and GLP-1, Hormone and metabolic 
research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 36 (2004) 761-
765. 
[34] E. Sebokova, A.D. Christ, H. Wang, S. Sewing, J.Z. Dong, J. Taylor, M.A. Cawthorne, M.D. 
Culler, Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in 
vivo potency, Endocrinology, 151 (2010) 2474-2482. 
[35] R. Goke, H.C. Fehmann, T. Linn, H. Schmidt, M. Krause, J. Eng, B. Goke, Exendin-4 is a 
high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like 
peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells, The Journal of biological 
chemistry, 268 (1993) 19650-19655. 
[36] A. Thum, K. Hupe-Sodmann, R. Goke, K. Voigt, B. Goke, G.P. McGregor, Endoproteolysis 
by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, 
exendins-3 and -4, Experimental and clinical endocrinology & diabetes : official journal, German 
Society of Endocrinology [and] German Diabetes Association, 110 (2002) 113-118. 
38 
 
[37] J.W. Neidigh, R.M. Fesinmeyer, K.S. Prickett, N.H. Andersen, Exendin-4 and glucagon-like-
peptide-1: NMR structural comparisons in the solution and micelle-associated states, 
Biochemistry, 40 (2001) 13188-13200. 
[38] J.G. Lee, J.H. Ryu, S.M. Kim, M.Y. Park, S.H. Kim, Y.G. Shin, J.W. Sohn, H.H. Kim, Z.Y. 
Park, J.Y. Seong, J.I. Kim, Replacement of the C-terminal Trp-cage of exendin-4 with a fatty 
acid improves therapeutic utility, Biochem Pharmacol, 151 (2018) 59-68. 
[39] L. Simonsen, J.J. Holst, C.F. Deacon, Exendin-4, but not glucagon-like peptide-1, is cleared 
exclusively by glomerular filtration in anaesthetised pigs, Diabetologia, 49 (2006) 706-712. 
[40] K. Copley, K. McCowen, R. Hiles, L.L. Nielsen, A. Young, D.G. Parkes, Investigation of 
exenatide elimination and its in vivo and in vitro degradation, Curr Drug Metab, 7 (2006) 367-
374. 
[41] C. Thorkildsen, S. Neve, B.D. Larsen, E. Meier, J.S. Petersen, Glucagon-like peptide 1 
receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression 
in db/db mice, The Journal of pharmacology and experimental therapeutics, 307 (2003) 490-
496. 
[42] J. Rosenstock, D. Raccah, L. Koranyi, L. Maffei, G. Boka, P. Miossec, J.E. Gerich, Efficacy 
and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately 
controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-
X), Diabetes care, 36 (2013) 2945-2951. 
[43] R.E. Kontermann, Strategies for extended serum half-life of protein therapeutics, Curr Opin 
Biotechnol, 22 (2011) 868-876. 
[44] M. Erak, K. Bellmann-Sickert, S. Els-Heindl, A.G. Beck-Sickinger, Peptide chemistry 
toolbox - Transforming natural peptides into peptide therapeutics, Bioorganic & medicinal 
chemistry, (2018). 
[45] T.M. Frederiksen, P. Sonderby, L.A. Ryberg, P. Harris, J.T. Bukrinski, A.M. Scharff-
Poulsen, M.N. Elf-Lind, G.H. Peters, Oligomerization of a Glucagon-like Peptide 1 Analog: 
Bridging Experiment and Simulations, Biophysical journal, 109 (2015) 1202-1213. 
[46] D.B. Steensgaard, J.K. Thomsen, H.B. Olsen, L.B. Knudsen, The molecular basis for the 
delayed absorption of the once-daily human GLP-1 analoge, liraglutide, Diabetes, 57 (2008) 
A164-A164. 
[47] Y. Wang, A. Lomakin, S. Kanai, R. Alex, G.B. Benedek, Transformation of oligomers of 
lipidated peptide induced by change in pH, Molecular pharmaceutics, 12 (2015) 411-419. 
[48] A.A. Spector, Fatty acid binding to plasma albumin, Journal of lipid research, 16 (1975) 
165-179. 
[49] P. Kurtzhals, S. Havelund, I. Jonassen, B. Kiehr, U.D. Larsen, U. Ribel, J. Markussen, 
Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein 
interaction and correlation between binding affinity and timing of the insulin effect in vivo, The 
Biochemical journal, 312 ( Pt 3) (1995) 725-731. 
[50] C. Bertucci, E. Domenici, Reversible and covalent binding of drugs to human serum 
albumin: methodological approaches and physiological relevance, Curr Med Chem, 9 (2002) 
1463-1481. 
[51] K. Madsen, L.B. Knudsen, H. Agersoe, P.F. Nielsen, H. Thogersen, M. Wilken, N.L. 
Johansen, Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 
derivatives: importance of fatty acid length, polarity, and bulkiness, Journal of medicinal 
chemistry, 50 (2007) 6126-6132. 
[52] L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt, N.L. Johansen, K. Madsen, F.Z. Pedersen, H. 
Thogersen, M. Wilken, H. Agerso, Potent derivatives of glucagon-like peptide-1 with 
pharmacokinetic properties suitable for once daily administration, Journal of medicinal 
chemistry, 43 (2000) 1664-1669. 
[53] J. Lau, P. Bloch, L. Schaffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L.B. 
Knudsen, J. McGuire, D.B. Steensgaard, H.M. Strauss, D.X. Gram, S.M. Knudsen, F.S. Nielsen, 
39 
 
P. Thygesen, S. Reedtz-Runge, T. Kruse, Discovery of the Once-Weekly Glucagon-Like 
Peptide-1 (GLP-1) Analogue Semaglutide, Journal of medicinal chemistry, 58 (2015) 7370-
7380. 
[54] D. Russell-Jones, Molecular, pharmacological and clinical aspects of liraglutide, a once-
daily human GLP-1 analogue, Molecular and cellular endocrinology, 297 (2009) 137-140. 
[55] E. Watson, D.M. Jonker, L.V. Jacobsen, S.H. Ingwersen, Population pharmacokinetics of 
liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and 
subjects with type 2 diabetes, and comparison to twice-daily exenatide, Journal of clinical 
pharmacology, 50 (2010) 886-894. 
[56] Y. Wang, A. Lomakin, S. Kanai, R. Alex, S. Belli, M. Donzelli, G.B. Benedek, The molecular 
basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or 
binding to serum albumin?, Journal of controlled release : official journal of the Controlled 
Release Society, 241 (2016) 25-33. 
[57] A. Plum, L.B. Jensen, J.B. Kristensen, In vitro protein binding of liraglutide in human plasma 
determined by reiterated stepwise equilibrium dialysis, Journal of pharmaceutical sciences, 102 
(2013) 2882-2888. 
[58] M. Malm-Erjefalt, I. Bjornsdottir, J. Vanggaard, H. Helleberg, U. Larsen, B. Oosterhuis, J.J. 
van Lier, M. Zdravkovic, A.K. Olsen, Metabolism and excretion of the once-daily human 
glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by 
dipeptidyl peptidase IV and neutral endopeptidase, Drug metabolism and disposition: the 
biological fate of chemicals, 38 (2010) 1944-1953. 
[59] C. Sorli, S.I. Harashima, G.M. Tsoukas, J. Unger, J.D. Karsbol, T. Hansen, S.C. Bain, 
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with 
type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, 
multinational, multicentre phase 3a trial, The lancet. Diabetes & endocrinology, 5 (2017) 251-
260. 
[60] J. Jiang, J. Zhang, L.V. Jacobsen, P. Hu, The pharmacokinetics, pharmacodynamics, and 
tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous 
administration in healthy Chinese male subjects, Journal of clinical pharmacology, 51 (2011) 
1620-1627. 
[61] C. Kapitza, L. Nosek, L. Jensen, H. Hartvig, C.B. Jensen, A. Flint, Semaglutide, a once-
weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral 
contraceptive, ethinylestradiol/levonorgestrel, Journal of clinical pharmacology, 55 (2015) 497-
504. 
[62] K.A. Lyseng-Williamson, Coagulation Factor IX (Recombinant), Albumin Fusion Protein 
(Albutrepenonacog Alfa; Idelvion(R)): A Review of Its Use in Haemophilia B, Drugs, 77 (2017) 
97-106. 
[63] C. Chaudhury, S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, D.C. Roopenian, C.L. 
Anderson, The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds 
albumin and prolongs its lifespan, The Journal of experimental medicine, 197 (2003) 315-322. 
[64] J. Kim, C.L. Bronson, W.L. Hayton, M.D. Radmacher, D.C. Roopenian, J.M. Robinson, C.L. 
Anderson, Albumin turnover: FcRn-mediated recycling saves as much albumin from 
degradation as the liver produces, Am J Physiol Gastrointest Liver Physiol, 290 (2006) G352-
360. 
[65] D. Sleep, J. Cameron, L.R. Evans, Albumin as a versatile platform for drug half-life 
extension, Biochim Biophys Acta, 1830 (2013) 5526-5534. 
[66] M.A. Young, J.A. Wald, J.E. Matthews, R. Scott, R.J. Hodge, H. Zhi, R.R. Reinhardt, 
Clinical pharmacology of albiglutide, a GLP-1 receptor agonist, Postgraduate medicine, 126 
(2014) 84-97. 
[67] W.R. Strohl, Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make 
Biobetters, BioDrugs, 29 (2015) 215-239. 
40 
 
[68] S. Tzaban, R.H. Massol, E. Yen, W. Hamman, S.R. Frank, L.A. Lapierre, S.H. Hansen, J.R. 
Goldenring, R.S. Blumberg, W.I. Lencer, The recycling and transcytotic pathways for IgG 
transport by FcRn are distinct and display an inherent polarity, J Cell Biol, 185 (2009) 673-684. 
[69] T. Suzuki, A. Ishii-Watabe, M. Tada, T. Kobayashi, T. Kanayasu-Toyoda, T. Kawanishi, T. 
Yamaguchi, Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins 
containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal 
antibodies and Fc-fusion proteins to human neonatal FcR, Journal of immunology, 184 (2010) 
1968-1976. 
[70] D.M. Kim, S.H. Chu, S. Kim, Y.W. Park, S.S. Kim, Fc fusion to Glucagon-like peptide-1 
inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent 
activity for human GLP-1 receptor activation, BMB reports, 42 (2009) 212-216. 
[71] T. Rath, K. Baker, J.A. Dumont, R.T. Peters, H. Jiang, S.W. Qiao, W.I. Lencer, G.F. Pierce, 
R.S. Blumberg, Fc-fusion proteins and FcRn: structural insights for longer-lasting and more 
effective therapeutics, Crit Rev Biotechnol, 35 (2015) 235-254. 
[72] P. Bruhns, B. Iannascoli, P. England, D.A. Mancardi, N. Fernandez, S. Jorieux, M. Daeron, 
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human 
IgG subclasses, Blood, 113 (2009) 3716-3725. 
[73] D.M. Czajkowsky, J. Hu, Z. Shao, R.J. Pleass, Fc-fusion proteins: new developments and 
future perspectives, EMBO molecular medicine, 4 (2012) 1015-1028. 
[74] W. Glaesner, A.M. Vick, R. Millican, B. Ellis, S.H. Tschang, Y. Tian, K. Bokvist, M. Brenner, 
A. Koester, N. Porksen, G. Etgen, T. Bumol, Engineering and characterization of the long-acting 
glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein, Diabetes-Metab Res, 26 
(2010) 287-296. 
[75] E.M. Agency., Trulicity assessment report, 2014. 
[76] K.S. Oh, J.Y. Kim, B.D. Yoon, M. Lee, H. Kim, M. Kim, J.H. Seo, S.H. Yuk, Sol-gel 
transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 
diabetes mellitus, European Journal of Pharmaceutics and Biopharmaceutics, 88 (2014) 664-
669. 
[77] M. Perez-Ortiz, C. Zapata-Urzua, G.A. Acosta, A. Alvarez-Lueje, F. Albericio, M.J. Kogan, 
Gold nanoparticles as an efficient drug delivery system for GLP-1 peptides, Colloids Surf B 
Biointerfaces, 158 (2017) 25-32. 
[78] A. Huotari, W. Xu, J. Monkare, M. Kovalainen, K.H. Herzig, V.P. Lehto, K. Jarvinen, Effect 
of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, 
release and biological activity, International journal of pharmaceutics, 454 (2013) 67-73. 
[79] A. Kovalchuk, W. Fischer, M. Epple, Controlled release of goserelin from microporous 
polyglycolide and polylactide, Macromolecular bioscience, 5 (2005) 289-298. 
[80] H. Okada, Y. Doken, Y. Ogawa, H. Toguchi, Preparation of three-month depot injectable 
microspheres of leuprorelin acetate using biodegradable polymers, Pharmaceutical research, 11 
(1994) 1143-1147. 
[81] LUPRON DEPOT® (leuprolide acetate for depot suspension) [prescribing information]. 
. 
[82] M.B. DeYoung, L. MacConell, V. Sarin, M. Trautmann, P. Herbert, Encapsulation of 
Exenatide in Poly-(D,L-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-
Acting Once-Weekly Formulation for Type 2 Diabetes, Diabetes technology & therapeutics, 13 
(2011) 1145-1154. 
[83] M. Fineman, S. Flanagan, K. Taylor, M. Aisporna, L.Z. Shen, K.F. Mace, B. Walsh, M. 
Diamant, B. Cirincione, P. Kothare, W.I. Li, L. MacConell, Pharmacokinetics and 
pharmacodynamics of exenatide extended-release after single and multiple dosing, Clinical 
pharmacokinetics, 50 (2011) 65-74. 
[84] R.R. Henry, J. Rosenstock, D. Logan, T. Alessi, K. Luskey, M.A. Baron, Continuous 
subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and 
41 
 
weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, Journal of diabetes 
and its complications, 28 (2014) 393-398. 
[85] I. Intarcia Therapeutics, Intarcia Announces FDA Filing Acceptance of New Drug 
Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes, 2017. 
[86] R.R. Henry, D. Logan, T. Alessi, M.A. Baron, A randomized, open-label, multicenter, 4-
week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 
diabetes, Clinical therapeutics, 35 (2013) 634-645 e631. 
[87] J.Y. Shu, B. Panganiban, T. Xu, Peptide-polymer conjugates: from fundamental science to 
application, Annu Rev Phys Chem, 64 (2013) 631-657. 
[88] S.H. Lee, S. Lee, Y.S. Youn, D.H. Na, S.Y. Chae, Y. Byun, K.C. Lee, Synthesis, 
characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1, Bioconjug 
Chem, 16 (2005) 377-382. 
[89] A Study for Patients With Type 2 Diabetes Mellitus. 
[90] V. Schellenberger, C.W. Wang, N.C. Geething, B.J. Spink, A. Campbell, W. To, M.D. 
Scholle, Y. Yin, Y. Yao, O. Bogin, J.L. Cleland, J. Silverman, W.P. Stemmer, A recombinant 
polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner, Nat 
Biotechnol, 27 (2009) 1186-1190. 
[91] V.N. Podust, B.C. Sim, D. Kothari, L. Henthorn, C. Gu, C.W. Wang, B. McLaughlin, V. 
Schellenberger, Extension of in vivo half-life of biologically active peptides via chemical 
conjugation to XTEN protein polymer, Protein Eng Des Sel, 26 (2013) 743-753. 
[92] D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, D. Zhuang, L. Porter, D.-S. 
Group, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a 
randomised, open-label, non-inferiority study, Lancet, 372 (2008) 1240-1250. 
[93] M.S. Fineman, B.B. Cirincione, D. Maggs, M. Diamant, GLP-1 based therapies: differential 
effects on fasting and postprandial glucose, Diabetes, obesity & metabolism, 14 (2012) 675-
688. 
[94] F. Calara, K. Taylor, J. Han, E. Zabala, E.M. Carr, M. Wintle, M. Fineman, A randomized, 
open-label, crossover study examining the effect of injection site on bioavailability of exenatide 
(synthetic exendin-4), Clinical therapeutics, 27 (2005) 210-215. 
[95] J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. 
Blonde, L.-S. Group, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 
26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 374 
(2009) 39-47. 
[96] E. Jimenez-Solem, M.H. Rasmussen, M. Christensen, F.K. Knop, Dulaglutide, a long-acting 
GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes, 
Current opinion in molecular therapeutics, 12 (2010) 790-797. 
[97] M. Hompesch, A. Jones-Leone, M.C. Carr, J. Matthews, H. Zhi, M. Young, L. Morrow, R.R. 
Reinhardt, Albiglutide does not impair the counter-regulatory hormone response to 
hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in 
subjects with type 2 diabetes mellitus, Diabetes, obesity & metabolism, 17 (2015) 82-90. 
[98] M.A. Nauck, U. Niedereichholz, R. Ettler, J.J. Holst, C. Orskov, R. Ritzel, W.H. Schmiegel, 
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in 
healthy humans, Am J Physiol, 273 (1997) E981-988. 
[99] H. Linnebjerg, S. Park, P.A. Kothare, M.E. Trautmann, K. Mace, M. Fineman, I. Wilding, M. 
Nauck, M. Horowitz, Effect of exenatide on gastric emptying and relationship to postprandial 
glycemia in type 2 diabetes, Regulatory peptides, 151 (2008) 123-129. 
[100] M. Lorenz, C. Pfeiffer, A. Steinstrasser, R.H. Becker, H. Rutten, P. Ruus, M. Horowitz, 
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to 
postprandial glycemia, Regulatory peptides, 185 (2013) 1-8. 
42 
 
[101] M.A. Nauck, G. Kemmeries, J.J. Holst, J.J. Meier, Rapid tachyphylaxis of the glucagon-
like peptide 1-induced deceleration of gastric emptying in humans, Diabetes, 60 (2011) 1561-
1565. 
[102] M.M. Umapathysivam, M.Y. Lee, K.L. Jones, C.E. Annink, C.E. Cousins, L.G. Trahair, 
C.K. Rayner, M.J. Chapman, M.A. Nauck, M. Horowitz, A.M. Deane, Comparative effects of 
prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric 
emptying and glycemia, Diabetes, 63 (2014) 785-790. 
[103] S.I. Sherwani, H.A. Khan, A. Ekhzaimy, A. Masood, M.K. Sakharkar, Significance of 
HbA1c Test in Diagnosis and Prognosis of Diabetic Patients, Biomark Insights, 11 (2016) 95-
104. 
[104] J.M. Trujillo, W. Nuffer, S.L. Ellis, GLP-1 receptor agonists: a review of head-to-head 
clinical studies, Ther Adv Endocrinol Metab, 6 (2015) 19-28. 
[105] T. Blevins, J. Pullman, J. Malloy, P. Yan, K. Taylor, C. Schulteis, M. Trautmann, L. Porter, 
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control 
compared with exenatide twice daily in patients with type 2 diabetes, The Journal of clinical 
endocrinology and metabolism, 96 (2011) 1301-1310. 
[106] J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, H. Hu, K. Wilhelm, M. Trautmann, 
L.Z. Shen, L.E. Porter, D.-S. Group, DURATION-1: exenatide once weekly produces sustained 
glycemic control and weight loss over 52 weeks, Diabetes care, 33 (2010) 1255-1261. 
[107] K.M. Dungan, S.T. Povedano, T. Forst, J.G. Gonzalez, C. Atisso, W. Sealls, J.L. 
Fahrbach, Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients 
with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial, 
Lancet, 384 (2014) 1349-1357. 
[108] R.E. Pratley, M.A. Nauck, A.H. Barnett, M.N. Feinglos, F. Ovalle, I. Harman-Boehm, J. Ye, 
R. Scott, S. Johnson, M. Stewart, J. Rosenstock, H.s. group, Once-weekly albiglutide versus 
once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs 
(HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study, The lancet. 
Diabetes & endocrinology, 2 (2014) 289-297. 
[109] J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, C.R. Heilmann, B.J. Hoogwerf, 
A. Gao, M.K. Boardman, M. Fineman, L. Porter, G. Schernthaner, Exenatide once weekly 
versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, 
open-label study, Lancet, 381 (2013) 117-124. 
[110] D.A. Scott, K.S. Boye, L. Timlin, J.F. Clark, J.H. Best, A network meta-analysis to compare 
glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or 
liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo, 
Diabetes, obesity & metabolism, 15 (2013) 213-223. 
[111] S. Kayaniyil, G. Lozano-Ortega, H.A. Bennett, K. Johnsson, A. Shaunik, S. Grandy, B. 
Kartman, A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 
Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus, Diabetes therapy : research, 
treatment and education of diabetes and related disorders, 7 (2016) 27-43. 
[112] W.B. Saunders, H. Nguyen, I. Kalsekar, Real-world glycemic outcomes in patients with 
type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective 
cohort study, Diabetes, metabolic syndrome and obesity : targets and therapy, 9 (2016) 217-
223. 
[113] J.G. Barrera, D.A. Sandoval, D.A. D'Alessio, R.J. Seeley, GLP-1 and energy balance: an 
integrated model of short-term and long-term control, Nature reviews. Endocrinology, 7 (2011) 
507-516. 
[114] J. van Can, B. Sloth, C.B. Jensen, A. Flint, E.E. Blaak, W.H. Saris, Effects of the once-
daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy 
metabolism in obese, non-diabetic adults, Int J Obes (Lond), 38 (2014) 784-793. 
43 
 
[115] J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, G. Exenatide-113 
Clinical Study, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in 
sulfonylurea-treated patients with type 2 diabetes, Diabetes care, 27 (2004) 2628-2635. 
[116] S.E. Kanoski, S.M. Fortin, M. Arnold, H.J. Grill, M.R. Hayes, Peripheral and central GLP-1 
receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor 
agonists, liraglutide and exendin-4, Endocrinology, 152 (2011) 3103-3112. 
[117] A. Secher, J. Jelsing, A.F. Baquero, J. Hecksher-Sorensen, M.A. Cowley, L.S. Dalboge, 
G. Hansen, K.L. Grove, C. Pyke, K. Raun, L. Schaffer, M. Tang-Christensen, S. Verma, B.M. 
Witgen, N. Vrang, L. Bjerre Knudsen, The arcuate nucleus mediates GLP-1 receptor agonist 
liraglutide-dependent weight loss, The Journal of clinical investigation, 124 (2014) 4473-4488. 
[118] L.L. Baggio, Q. Huang, T.J. Brown, D.J. Drucker, A recombinant human glucagon-like 
peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-
dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis, 
Diabetes, 53 (2004) 2492-2500. 
[119] T.J. Moretto, D.R. Milton, T.D. Ridge, L.A. Macconell, T. Okerson, A.M. Wolka, R.G. 
Brodows, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-
naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-
group study, Clinical therapeutics, 30 (2008) 1448-1460. 
[120] V.A. Fonseca, R. Alvarado-Ruiz, D. Raccah, G. Boka, P. Miossec, J.E. Gerich, E.F.C.G.-
M.S. Investigators, Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in 
monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 
diabetes (GetGoal-Mono), Diabetes care, 35 (2012) 1225-1231. 
[121] A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, I. Olvera-
Alvarez, P.M. Hale, M. Zdravkovic, B. Bode, L.-S. Group, Liraglutide versus glimepiride 
monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-
blind, parallel-treatment trial, Lancet, 373 (2009) 473-481. 
[122] G. Umpierrez, S. Tofe Povedano, F. Perez Manghi, L. Shurzinske, V. Pechtner, Efficacy 
and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized 
controlled trial (AWARD-3), Diabetes care, 37 (2014) 2168-2176. 
[123] M.A. Nauck, M.W. Stewart, C. Perkins, A. Jones-Leone, F. Yang, C. Perry, R.R. 
Reinhardt, M. Rendell, Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide 
(HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in 
patients with type 2 diabetes mellitus inadequately controlled with diet and exercise, 
Diabetologia, 59 (2016) 266-274. 
[124] D. Russell-Jones, R.M. Cuddihy, M. Hanefeld, A. Kumar, J.G. Gonzalez, M. Chan, A.M. 
Wolka, M.K. Boardman, D.-S. Group, Efficacy and safety of exenatide once weekly versus 
metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 
diabetes (DURATION-4): a 26-week double-blind study, Diabetes care, 35 (2012) 252-258. 
[125] M. Marre, J. Shaw, M. Brandle, W.M. Bebakar, N.A. Kamaruddin, J. Strand, M. 
Zdravkovic, T.D. Le Thi, S. Colagiuri, L.-S.s. group, Liraglutide, a once-daily human GLP-1 
analogue, added to a sulphonylurea over 26 weeks produces greater improvements in 
glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with 
Type 2 diabetes (LEAD-1 SU), Diabetic medicine : a journal of the British Diabetic Association, 
26 (2009) 268-278. 
[126] J.M. Trujillo, W. Nuffer, GLP-1 receptor agonists for type 2 diabetes mellitus: recent 
developments and emerging agents, Pharmacotherapy, 34 (2014) 1174-1186. 
[127] R. Gentilella, C. Bianchi, A. Rossi, C.M. Rotella, Exenatide: a review from pharmacology 
to clinical practice, Diabetes, obesity & metabolism, 11 (2009) 544-556. 
[128] B. Ahren, A. Leguizamo Dimas, P. Miossec, S. Saubadu, R. Aronson, Efficacy and safety 
of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately 
controlled on metformin (GetGoal-M), Diabetes care, 36 (2013) 2543-2550. 
44 
 
[129] G.B. Bolli, M. Munteanu, S. Dotsenko, E. Niemoeller, G. Boka, Y. Wu, M. Hanefeld, 
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes 
insufficiently controlled on metformin (GetGoal-F1), Diabetic medicine : a journal of the British 
Diabetic Association, 31 (2014) 176-184. 
[130] M. Pinget, R. Goldenberg, E. Niemoeller, I. Muehlen-Bartmer, H. Guo, R. Aronson, 
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently 
controlled on pioglitazone (GetGoal-P), Diabetes, obesity & metabolism, 15 (2013) 1000-1007. 
[131] J. Rosenstock, B. Guerci, M. Hanefeld, S. Gentile, R. Aronson, F.J. Tinahones, C. Roy-
Duval, E. Souhami, M. Wardecki, J. Ye, R. Perfetti, S. Heller, I. GetGoal Duo-2 Trial, Prandial 
Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin 
Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal 
Duo-2 Trial, Diabetes care, 39 (2016) 1318-1328. 
[132] J. Rosenstock, M. Hanefeld, P. Shamanna, K.W. Min, G. Boka, P. Miossec, T. Zhou, I. 
Muehlen-Bartmer, R.E. Ratner, Beneficial effects of once-daily lixisenatide on overall and 
postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes 
inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S), Journal of 
diabetes and its complications, 28 (2014) 386-392. 
[133] Y. Seino, K.W. Min, E. Niemoeller, A. Takami, E.G.-L.A.S. Investigators, Randomized, 
double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in 
Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a 
sulfonylurea (GetGoal-L-Asia), Diabetes, obesity & metabolism, 14 (2012) 910-917. 
[134] C. Yu Pan, P. Han, X. Liu, S. Yan, P. Feng, Z. Zhou, X. Lv, H. Tian, Y. Jin Kui, B. Su, S. 
Shang, E. Niemoeller, Lixisenatide treatment improves glycaemic control in Asian patients with 
type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a 
randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia), 
Diabetes/metabolism research and reviews, 30 (2014) 726-735. 
[135] B. Ahren, S.L. Johnson, M. Stewart, D.T. Cirkel, F. Yang, C. Perry, M.N. Feinglos, H.S. 
Group, HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial 
assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and 
glimepiride in patients with type 2 diabetes taking metformin, Diabetes care, 37 (2014) 2141-
2148. 
[136] P.D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M.C. Carr, Efficacy 
and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 
diabetes currently taking metformin and glimepiride: HARMONY 5, Diabetes, obesity & 
metabolism, 17 (2015) 179-187. 
[137] J. Reusch, M.W. Stewart, C.M. Perkins, D.T. Cirkel, J. Ye, C.R. Perry, R.R. Reinhardt, 
B.W. Bode, Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist 
albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-
blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on 
pioglitazone, with or without metformin, Diabetes, obesity & metabolism, 16 (2014) 1257-1264. 
[138] P.N. Weissman, M.C. Carr, J. Ye, D.T. Cirkel, M. Stewart, C. Perry, R. Pratley, 
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in 
patients with type 2 diabetes inadequately controlled with metformin with or without 
sulfonylurea, Diabetologia, 57 (2014) 2475-2484. 
[139] L. Blonde, J. Jendle, J. Gross, V. Woo, H. Jiang, J.L. Fahrbach, Z. Milicevic, Once-weekly 
dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in 
patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority 
study, Lancet, 385 (2015) 2057-2066. 
[140] F. Giorgino, M. Benroubi, J.H. Sun, A.G. Zimmermann, V. Pechtner, Efficacy and Safety of 
Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on 
Metformin and Glimepiride (AWARD-2), Diabetes care, 38 (2015) 2241-2249. 
45 
 
[141] M. Nauck, R.S. Weinstock, G.E. Umpierrez, B. Guerci, Z. Skrivanek, Z. Milicevic, Efficacy 
and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized 
controlled trial (AWARD-5), Diabetes care, 37 (2014) 2149-2158. 
[142] C. Wysham, T. Blevins, R. Arakaki, G. Colon, P. Garcia, C. Atisso, D. Kuhstoss, M. 
Lakshmanan, Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus 
exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1), Diabetes care, 37 
(2014) 2159-2167. 
[143] M.A. Nauck, S. Duran, D. Kim, D. Johns, J. Northrup, A. Festa, R. Brodows, M. 
Trautmann, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with 
type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-
inferiority study, Diabetologia, 50 (2007) 259-267. 
[144] M.S. Fineman, K.F. Mace, M. Diamant, T. Darsow, B.B. Cirincione, T.K. Booker Porter, 
L.A. Kinninger, M.E. Trautmann, Clinical relevance of anti-exenatide antibodies: safety, efficacy 
and cross-reactivity with long-term treatment, Diabetes, obesity & metabolism, 14 (2012) 546-
554. 
[145] S.C. Jones, D.L. Ryan, V.S. Pratt, A. Niak, A.D. Brinker, Injection-Site Nodules Associated 
With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug 
Administration Adverse Event Reporting System, Diabetes Spectr, 28 (2015) 283-288. 
[146] L. Blonde, D. Russell-Jones, The safety and efficacy of liraglutide with or without oral 
antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies, Diabetes, 
obesity & metabolism, 11 Suppl 3 (2009) 26-34. 
[147] L.A. Leiter, M.C. Carr, M. Stewart, A. Jones-Leone, R. Scott, F. Yang, Y. Handelsman, 
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in 
patients with type 2 diabetes and renal impairment: a randomized phase III study, Diabetes 
care, 37 (2014) 2723-2730. 
[148] J. Rosenstock, V.A. Fonseca, J.L. Gross, R.E. Ratner, B. Ahren, F.C. Chow, F. Yang, D. 
Miller, S.L. Johnson, M.W. Stewart, L.A. Leiter, G. Harmony 6 Study, Advancing basal insulin 
replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a 
comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial 
insulin lispro, Diabetes care, 37 (2014) 2317-2325. 
[149] B. Gier, A.V. Matveyenko, D. Kirakossian, D. Dawson, S.M. Dry, P.C. Butler, Chronic 
GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and 
accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse 
model, Diabetes, 61 (2012) 1250-1262. 
[150] M. Elashoff, A.V. Matveyenko, B. Gier, R. Elashoff, P.C. Butler, Pancreatitis, pancreatic, 
and thyroid cancer with glucagon-like peptide-1-based therapies, Gastroenterology, 141 (2011) 
150-156. 
[151] A.G. Egan, E. Blind, K. Dunder, P.A. de Graeff, B.T. Hummer, T. Bourcier, C. 
Rosebraugh, Pancreatic safety of incretin-based drugs--FDA and EMA assessment, The New 
England journal of medicine, 370 (2014) 794-797. 
[152] L. Bjerre Knudsen, L.W. Madsen, S. Andersen, K. Almholt, A.S. de Boer, D.J. Drucker, C. 
Gotfredsen, F.L. Egerod, A.C. Hegelund, H. Jacobsen, S.D. Jacobsen, A.C. Moses, A.M. Molck, 
H.S. Nielsen, J. Nowak, H. Solberg, T.D. Thi, M. Zdravkovic, U. Moerch, Glucagon-like Peptide-
1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell 
proliferation, Endocrinology, 151 (2010) 1473-1486. 
[153] L. Hegedus, A.C. Moses, M. Zdravkovic, T. Le Thi, G.H. Daniels, GLP-1 and calcitonin 
concentration in humans: lack of evidence of calcitonin release from sequential screening in 
over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human 
GLP-1 analog, liraglutide, The Journal of clinical endocrinology and metabolism, 96 (2011) 853-
860. 
46 
 
[154] C. Alves, F. Batel-Marques, A.F. Macedo, A meta-analysis of serious adverse events 
reported with exenatide and liraglutide: acute pancreatitis and cancer, Diabetes research and 
clinical practice, 98 (2012) 271-284. 
[155] R. Balena, I.E. Hensley, S. Miller, A.H. Barnett, Combination therapy with GLP-1 receptor 
agonists and basal insulin: a systematic review of the literature, Diabetes, obesity & metabolism, 
15 (2013) 485-502. 
[156] J.B. Buse, T. Vilsboll, J. Thurman, T.C. Blevins, I.H. Langbakke, S.G. Bottcher, H.W. 
Rodbard, N.N.T. Investigators, Contribution of liraglutide in the fixed-ratio combination of insulin 
degludec and liraglutide (IDegLira), Diabetes care, 37 (2014) 2926-2933. 
[157] V.R. Aroda, J. Rosenstock, C. Wysham, J. Unger, D. Bellido, G. Gonzalez-Galvez, A. 
Takami, H. Guo, E. Niemoeller, E. Souhami, R.M. Bergenstal, L.T.I. LixiLan, Efficacy and Safety 
of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 
Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized 
Trial, Diabetes care, 39 (2016) 1972-1980. 
[158] J.S. Skyler, G.L. Bakris, E. Bonifacio, T. Darsow, R.H. Eckel, L. Groop, P.H. Groop, Y. 
Handelsman, R.A. Insel, C. Mathieu, A.T. McElvaine, J.P. Palmer, A. Pugliese, D.A. Schatz, 
J.M. Sosenko, J.P. Wilding, R.E. Ratner, Differentiation of Diabetes by Pathophysiology, Natural 
History, and Prognosis, Diabetes, 66 (2017) 241-255. 
[159] Standards of Medical Care in Diabetes-2017: Summary of Revisions, Diabetes care, 40 
(2017) S4-S5. 
[160] T.P.I. Ltd., TEVA SETTLES PATENT LITIGATION WITH ASTRAZENECA ALLOWING 
TEVA TO COMMERCIALIZE ITS GENERIC VERSION OF BYETTA® (EXENATIDE 
INJECTION) IN THE UNITED STATES, 2016. 
[161] A. Pharma., ANTARES PHARMA ANNOUNCES SETTLEMENT OF PATENT 
LITIGATION FOR KEY ALLIANCE BUSINESS PRODUCT, 2016. 
[162] N.N. A/S., Novo Nordisk Annual Report 2011, 2012. 
[163] I. Amylin Pharmaceuticals, Notice of Annual Stockholders’ Meeting, Proxy Statement and 
2011 Annual Report, 2012. 
[164] N. Nordisk., Victoza® (liraglutide) is approved in the US as the only type 2 diabetes 
treatment indicated to reduce the risk of three major adverse cardiovascular events, 2017. 
[165] Saxenda® (liraglutide) injection [prescribing information]. Bagsvaerd, Denmark: Novo 
Nordisk ; 2017 
 
[166] N.N. A/S., Novo Nordisk Annual Report 2017, 2018. 
[167] A. PLC., AstraZeneca Annual Report and Form 20-F Information 2013, 2014. 
[168] N.N. A/S., Novo Nordisk Annual Report 2013, 2014. 
[169] Bydureon® BCise (exenatide sustained-release) for injectable suspension [prescribing 
information]. Wilmington, DE: Astrazeneca Pharmaceuticals LP; 2017. 
[170] G. plc., Annual report 2015, 2016. 
[171] N.N. A/S., Novo Nordisk Annual Report 2015, 2016. 
[172] E.S.H. Company., 2017 Express Scripts National Preferred Formulary, 2017. 
[173] GSK., Discontinuation of TANZEUM® (albiglutide), 2017. 
[174] E.L.a. Company., 2016 Financial Report, 2017. 
[175] E.L.a. Company., ELI LILLY AND COMPANY 2015 ANNUAL REPORT AND PROXY 
STATEMENT, 2016. 
[176] E.L.a. Company., Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue 
Growth, Increases 2018 EPS Guidance, 2018. 
[177] S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. Jodar, L.A. Leiter, I. Lingvay, J. 
Rosenstock, J. Seufert, M.L. Warren, V. Woo, O. Hansen, A.G. Holst, J. Pettersson, T. Vilsboll, 
S.-. Investigators, Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, 
The New England journal of medicine, 375 (2016) 1834-1844. 
47 
 
[178] A. PLC., AstraZeneca Annual Report and Form 20-F Information 2016, 2017. 
[179] A. PLC., Full-Year 2017 Results, 2018. 
[180] N.N. A/S., Financial report for the period 1 January 2017 to 30 June 2017, 2017. 
[181] G. plc., Annual report 2016, 2017. 
[182] G. plc., Full year and fourth quarter 2017, 2018. 
[183] Sanofi., Annual Report on Form 20-F 2016, 2017. 
[184] Sanofi., Sanofi Delivers 2017 Business EPS in line with Guidance, 2018. 
[185] S.A. Ross, Breaking down patient and physician barriers to optimize glycemic control in 
type 2 diabetes, The American journal of medicine, 126 (2013) S38-48. 
[186] A.Z. Fu, Y. Qiu, L. Radican, Impact of fear of insulin or fear of injection on treatment 
outcomes of patients with diabetes, Current medical research and opinion, 25 (2009) 1413-
1420. 
[187] J. Pfutzner, J. Hellhammer, P. Musholt, A.H. Pfutzner, J. Bohnke, H. Torsten, I. Amann-
Zalan, M. Ganz, T. Forst, A. Pfutzner, Evaluation of dexterity in insulin-treated patients with type 
1 and type 2 diabetes mellitus, J Diabetes Sci Technol, 5 (2011) 158-165. 
[188] T.A. Baekdal, M. Thomsen, V. Kupcova, C.W. Hansen, T.W. Anderson, Pharmacokinetics, 
Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment, Journal of 
clinical pharmacology, (2018). 
[189] D. Malkov, R. Angelo, H.Z. Wang, E. Flanders, H. Tang, I. Gomez-Orellana, Oral delivery 
of insulin with the eligen technology: mechanistic studies, Curr Drug Deliv, 2 (2005) 191-197. 
[190] J.J. Holst, S. Madsbad, Semaglutide seems to be more effective the other GLP-1Ras, Ann 
Transl Med, 5 (2017) 505. 
[191] M. Davies, T.R. Pieber, M.L. Hartoft-Nielsen, O.K.H. Hansen, S. Jabbour, J. Rosenstock, 
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on 
Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial, JAMA, 318 
(2017) 1460-1470. 
[192] C. Kapitza, L. Nosek, L. Jensen, H. Hartvig, C.B. Jensen, A. Flint, Semaglutide, a Once-
Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral 
Contraceptive, Ethinylestradiol/Levonorgestrel, Journal of clinical pharmacology, 55 (2015) 497-
504. 
[193] N. Nordisk., Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, 
with oral semaglutide, 2018. 
[194] Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes 
Mellitus. 
[195] O. Pharmaceuticals. 
[196] A. Leone-Bay, M. Grant, S. Greene, G. Stowell, S. Daniels, A. Smithson, S. Villanueva, S. 
Cope, K. Carrera, S. Reyes, P. Richardson, Evaluation of novel particles as an inhalation 
system for GLP-1, Diabetes, obesity & metabolism, 11 (2009) 1050-1059. 
[197] M.T. Marino, D. Costello, R. Baughman, A. Boss, J. Cassidy, C. Damico, S. van Marle, A. 
van Vliet, P.C. Richardson, Pharmacokinetics and pharmacodynamics of inhaled GLP-1 
(MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 
diabetes, Clin Pharmacol Ther, 88 (2010) 243-250. 
[198] Y. Shahzad, R. Louw, M. Gerber, J. du Plessis, Breaching the skin barrier through 
temperature modulations, Journal of controlled release : official journal of the Controlled 
Release Society, 202 (2015) 1-13. 
[199] W.T. Cefalu, J.S. Skyler, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, S. Cheng, R.A. 
Gelfand, G. Inhaled Insulin Study, Inhaled human insulin treatment in patients with type 2 
diabetes mellitus, Annals of internal medicine, 134 (2001) 203-207. 
[200] C. Black, E. Cummins, P. Royle, S. Philip, N. Waugh, The clinical effectiveness and cost-
effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic 
evaluation, Health Technol Assess, 11 (2007) 1-126. 
48 
 
[201] A.L. Smart, S. Gaisford, A.W. Basit, Oral peptide and protein delivery: intestinal obstacles 
and commercial prospects, Expert Opin Drug Deliv, 11 (2014) 1323-1335. 
[202] L. Heinemann, Y. Jacques, Oral insulin and buccal insulin: a critical reappraisal, J 
Diabetes Sci Technol, 3 (2009) 568-584. 
[203] P. Fonte, F. Araujo, S. Reis, B. Sarmento, Oral insulin delivery: how far are we?, J 
Diabetes Sci Technol, 7 (2013) 520-531. 
[204] P. Zarogoulidis, N. Papanas, G. Kouliatsis, D. Spyratos, K. Zarogoulidis, E. Maltezos, 
Inhaled insulin: too soon to be forgotten?, Journal of aerosol medicine and pulmonary drug 
delivery, 24 (2011) 213-223. 
[205] J. Mitri, A.G. Pittas, Inhaled insulin--what went wrong, Nat Clin Pract Endocrinol Metab, 5 
(2009) 24-25. 
[206] V. Patel, A. Joharapurkar, N. Dhanesha, S. Kshirsagar, K. Patel, R. Bahekar, G. Shah, M. 
Jain, Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity 
independent of its effect on appetite and body weight in diet-induced obese C57 mice, Can J 
Physiol Pharmacol, 91 (2013) 1009-1015. 
[207] A. Pocai, P.E. Carrington, J.R. Adams, M. Wright, G. Eiermann, L. Zhu, X. Du, A. Petrov, 
M.E. Lassman, G. Jiang, F. Liu, C. Miller, L.M. Tota, G. Zhou, X. Zhang, M.M. Sountis, A. 
Santoprete, E. Capito, G.G. Chicchi, N. Thornberry, E. Bianchi, A. Pessi, D.J. Marsh, R. 
SinhaRoy, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, 
Diabetes, 58 (2009) 2258-2266. 
[208] M.A. Deryabina, J.R. Daugaard, C.B. Knudsen, P.T. Shelton, J.U. Fog, L. Jessen, P. 
Noerregaard, Pharmacokinetics and Pharmacodynamics of GLP-1-GIP Receptor Dual Agonist 
Peptides: From Once-Daily to Once-Weekly, Diabetes, 64 (2015) A534-A534. 
[209] K. Fosgerau, L. Jessen, J. Lind Tolborg, T. Osterlund, K. Schaeffer Larsen, K. Rolsted, M. 
Brorson, J. Jelsing, T. Skovlund Ryge Neerup, The novel GLP-1-gastrin dual agonist, ZP3022, 
increases beta-cell mass and prevents diabetes in db/db mice, Diabetes, obesity & metabolism, 
15 (2013) 62-71. 
[210] H. Soni, Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat 
diabesity, Med Hypotheses, 95 (2016) 5-9. 
[211] S.J. Henderson, A. Konkar, D.C. Hornigold, J.L. Trevaskis, R. Jackson, M. Fritsch Fredin, 
R. Jansson-Lofmark, J. Naylor, A. Rossi, M.A. Bednarek, N. Bhagroo, H. Salari, S. Will, S. 
Oldham, G. Hansen, M. Feigh, T. Klein, J. Grimsby, S. Maguire, L. Jermutus, C.M. Rondinone, 
M.P. Coghlan, Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor 
peptide agonist in rodents and non-human primates, Diabetes Obesity & Metabolism, 18 (2016) 
1176-1190. 
[212] S. Chakradhar, All in one: Researchers create combination drugs for diabetes and obesity, 
Nat Med, 22 (2016) 694-696. 
[213] K. Fosgerau, L. Jessen, J.L. Tolborg, T. Osterlund, K.S. Larsen, K. Rolsted, M. Brorson, J. 
Jelsing, T.S.R. Neerup, The novel GLP-1-gastrin dual agonist, ZP3022, increases ss-cell mass 
and prevents diabetes in db/db mice, Diabetes Obesity & Metabolism, 15 (2013) 62-71. 
 
